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Abstract:
The  basic  aim  of  any  Bi-layer  tablet  formulation  is  to  separate  physically  or  chemically
incompatible ingredients and to produce repeat action or prolonged action tablet. The present
study  was  aimed  at  developing  a  bilayer  tablet  of  Acetaminophen  and  Methocarbamol.
Acetaminophen is used as an Analgesic, Non-Narcotic, antipyretic, Methocarbamol is used as an
Anti-inflammatory,  skeletal  muscle  relaxant.  Totally  9  formulations  are  prepared  with
Acetaminophen and Methocarbamol granules prepared separately in a rapid mixer granulator.
Pre compression parameters like Bulk density,  True density,  Angle of repose indicate all  the
formulations are showing good flow properties. Tablets are compressed using SEJONG bilayer
compression  machine  and  tablets  are  evaluated  for  post  compression  parameters  Weight
variation,  Hardness,  Friability,  Disintegration  and  Dissolution  parameters.  Among  all  the
formulations F8 is showing the release profile similar to the Innovator. The compressed bilayer
tablets was packed in blisters and subjected to stability studies at 40⁰C and 75% RH, 25⁰C and
60% RH. Samples were analyzed at regular intervals as mentioned in stability protocol. From the
study,  it  may be concluded that bilayer tablet of  Acetaminophen and Methocarbamol can be
prepared as immediate release formulation compared to conventional formulations.
1. INTRODUCTION
1.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS1,2,3,4,5,6,26
Prostaglandins are a family of chemicals that are produced by the cells of the body and have
several important functions. They promote inflammation, pain, and fever; support the blood
clotting function of platelets; and protect the lining of the stomach from the damaging effects
of acid.
         Prostaglandins are produced within the body cells by the enzyme cyclooxygenase
(COX).  There  are  two  COX  enzymes,  COX-1  and  COX-2.  Both  enzymes  produce
prostaglandins that promote inflammation, pain, and fever. However, only COX-1 produces
prostaglandins that support platelets. Non steroidal anti-inflammatory drugs (NSAIDs) block
the  COX  enzymes  and  reduce  prostaglandins  throughout  the  body.  As  a  consequence,
ongoing inflammation, pain, and fever are reduced. Since the prostaglandins that protect the
stomach and support platelets and blood clotting also are reduced, NSAIDs can cause ulcers
in the stomach and promote bleeding.
          NSAIDs vary in their potency, duration of action, how they are eliminated from the
body,  how strongly they  inhibit  COX-1  and  their  tendency to  cause  ulcers  and promote
bleeding. The more an NSAID blocks COX-1, the greater is its tendency to cause ulcers and
promote bleeding. One NSAID, celecoxib(Celebrex), blocks COX-2 but has little effect on
COX-1, and is therefore further classified as a selective COX-2 inhibitor. 
          Aspirin is a unique NSAID, not only because of its many uses, but because it is the
only NSAID that inhibits the clotting of blood for a prolonged period (4 to 7 days). Most
NSAIDs inhibit the clotting of blood for only a few hours. Ketorolac (Toradol) is a very
potent NSAID and is used for moderately severe acute pain that usually requires narcotics.
Ketorolac causes ulcers more frequently than other NSAID. Therefore, it is not used for more
than five days. 
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1.2 CLASSIFICATION7,8,9,10,11
NSAIDs can be classified based on their chemical structure or mechanism of action. Older
NSAIDs were known long before their mechanism of action was elucidated and were for this
reason classified by chemical structure or origin.
Salicylates
 Aspirin (acetylsalicylic acid)
 Diflunisal
 Salsalate
p-amino phenol derivatives
 Paracetamol
 phenacetin
Propionic acid derivatives
 Ibuprofen
 Naproxen
 Fenoprofen
 Ketoprofen
 Flurbiprofen
 Oxaprozin
 Loxoprofen
Acetic acid derivatives
 Indomethacin
 Sulindac
 Etodolac
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 Ketorolac
 Diclofenac
 Nabumetone
 Piroxicam
 Meloxicam
 Tenoxicam
 Droxicam
 Lornoxicam
 Isoxicam
Fenamic acid derivatives ( Fenamates )
 Mefenamic acid
 Meclofenamic acid
 Flufenamic acid
 Tolfenamic acid
Selective COX-2 inhibitors (Coxibs)
 Celecoxib
 Rofecoxib
 Valdecoxib
 Parecoxib
 Lumiracoxib
 Etoricoxib
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Sulphonanilides
 Nimesulide
Others
 Licofelone
1.3 ACETAMINOPHEN12,13,14,22,23
Acetaminophen (Paracetamol, APAP), is an over the counter pain reliever that also reduces
fever. It is commonly used to reduce pain associated with headaches, migraines, back ache,
cold,  and  flu.  Its  general  mechanism  of  action  is  inhibition  of  the  COX-2  enzyme.
 Acetaminophen belongs to a class of drugs called analgesics (pain relievers) and antipyretics
(fever reducers).  The  exact  mechanism  of  action  of  acetaminophen  is  not  known.
Acetaminophen relieves pain by elevating the pain threshold, that is, by requiring a greater
amount of pain to develop before a person feels. 
Analgesics15,16,17,18,28
Acetaminophen is used to provide temporary analgesia in the treatment of mild to moderate
pain.  The  drug  is  most  effective  in  relieving  low  intensity  pain  of  non-visceral  origin.
Acetaminophen does not have antirheumatic effects. Unlike salicylates and prototypical non-
steroidal  anti-inflammatory  agents  (NSAIAs),  acetaminophen  does  not  usually  depress
prothrombin  levels.  In  addition,  acetaminophen  produces  a  lower  incidence  of  gastric
irritation,  erosion,  or  bleeding  than  do  salicylates.  Acetaminophen  has  been  used  in  the
treatment of pain in various combinations with aspirin, caffeine, opiates, and/or other agents.
Acetaminophen  (650-mg  oral  doses)  in  combination  with  oral  doses  of  an  opiate  (e.g.,
codeine,  oxycodone)  produces  greater  analgesic  effect  than  that  produced  by  either
acetaminophen or higher doses of the opiate alone. In addition, there is little evidence that
such combinations cause fewer adverse effects than higher doses of the individual agents
alone.
Antipyretics19,20,21
Acetaminophen is used frequently to lower body temperature in febrile patients in whom
fever may be deleterious or in whom considerable relief is obtained when fever is lowered.
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However, antipyretic therapy is generally nonspecific, does not influence the course of the
underlying disease, and may obscure the patient's illness. Parents and caregivers of paediatric
patients should be reassured that while some parental anxiety. Over fever is understandable,
the principal reason for treating fever is for patient. Comfort and that complete normalization
of  body temperature  is  not  necessary and  may not  be possible.  To minimize  the  risk  of
acetaminophen  over  dosage,  alternative  antipyretics  should  be  considered  for  children  at
increased risk of developing toxicity and in those with refractory fever.
1.4 METHOCARBAMOL29
Methocarbamol is a central muscle relaxant for skeletal muscles, used to treat spasms. It is
structurally related  to  guaifenesin.  Methocarbamol's  exact  mechanism of  causing skeletal
muscle relaxation is unknown. It is thought to work centrally, perhaps by general depressant
effects. It has no direct relaxant effects on striated muscle, nerve fibers, or the motor endplate.
It  will  not  directly relax  contracted skeletal  muscles.  The drug has  a  secondary sedative
effect.
SKELETAL MUSCLE SPASMOLYTICS29
Muscle spasticity is a characteristic of many clinical conditions, including trauma, myositis,
muscular and ligamentous sprains and strains, intervertebral disk disease, tetanus, strychnine
poisoning, neurologic disorders, and exertional rhabdomyolysis. An increase in tonic stretch
reflexes originates from the CNS with involvement of descending pathways and results in
hyper excitability of motor neurons in the spinal cord. Drug therapy alleviates muscle spasms
by modifying the stretch reflex arc or by interfering with the excitation-coupling process in
the  muscle  itself.  Centrally  acting  muscle  relaxants  block  interneuronal  pathways  in  the
spinal cord and in the midbrain reticular activating system. Some drugs also have sedative
effects, which are beneficial to anxious, painful animals. The hydantoin derivatives have a
direct action on muscle.
Methocarbamol is a centrally acting muscle relaxant chemically related to guaifenesin. Its
exact mechanism of action is unknown, and it has no direct relaxant effect on striated muscle,
nerve fibers, or the motor endplate. It also has a sedative effect. In dogs, cats, and horses,
methocarbamol  is  indicated  as  adjunct  therapy  of  acute  inflammatory  and  traumatic
conditions of skeletal muscle and to reduce muscle spasms.
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Guaifenesin (glyceryl guaiacolate) is a centrally acting muscle relaxant that is believed to
depress  or  block  nerve  impulse  transmission  at  the  internuncial  neuron  level  of  the
subcortical areas of the brain, brain stem, and spinal  cord.  It  also has mild analgesic and
sedative  actions.  Guaifenesin  is  given  IV  to  induce  muscle  relaxation  as  an  adjunct  to
anesthesia for short procedures. It relaxes both laryngeal and pharyngeal muscles, allowing
easier intubation, but has little effect on diaphragm and respiratory function. It may cause
transient increases in cardiac rate and decreases in blood pressure.
1.5  TABLETS30,31,32
Tablets are solid unit dosage form, flat or biconvex in shape, prepared by may be swallowed
whole or being chewed.  Some are dissolved or dispersed in water   before administration.
Implants or passeries may also be presented in the form of tablet. Tablet may vary in shape
and differ greatly in size and weight depending on the amount of medicinal substance and the
intended mode of administration.
1.5.1 Advantages of tablet
• Large  scale  manufacturing  is  feasible  in  comparison  to  other  dosage  forms.
Therefore, economy can be achieved.
• Accuracy of dose is maintained since tablet is a solid unit dosage form.
• Longer expiry period and minimum microbial spillage owing to lower moisture
content.
• As tablet is not a sterile dosage form, stringent environmental conditions are not
required in the tablet department.
• Ease of packaging (blister or strip) and easy handling over liquid dosage form.
• Easy to transport in bulk. Emergency supplies can be carried by patients.
• Organoleptic  properties  (taste,  appearance  and  odour)  are  best  improved  by
coating of tablet.
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• Product  identification  is  easy  and  markings  done  with  the  help  of  grooved
punches and printing with edible ink.
• Different  types  of  tablets  are  available  like  buccal,  floating,  colon  targeting,
effervescent, dispersible, soluble, and chewable, etc.
• In comparison to parenterals dosage form, a doctor or a nurse is not required for
administration. I.e. self-administration is possible.
• In comparison to capsules, tablets are more tamperproof.
1.5.2 Disadvantages of tablet
• It  is  difficult  to  convert  a  high dose  poorly compressible API into a  tablet  of
suitable size for human use.
• Difficult to formulate a drug with poor wettability, slow dissolution into a tablet.
• Slow onset of action as compared to parenterals, liquid orals and capsules.
• The amount of liquid drug (e.g. Vitamin E, Simethicone) that can be trapped into a
tablet is very less.
• Difficult to swallow for kids, terminally ill and geriatric patients.
• Patients undergoing radiotherapy cannot swallow tablet.
1.6  TYPES OF TABLETS31,32,33
With advancement in technology and increase in awareness towards modification in standard
tablet to achieve better  bioavailability,  newer and more efficient  tablet  dosage forms are
being developed.
To understand each dosage form, tablets here are classified by their route of administration.
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A) Oral tablets for ingestion
These tablets are meant to be swallowed intact along with a sufficient quantity of potable
water.  Exception  is  chewable  tablet.  Over  90%  of  the  tablets  manufactured  today  are
ingested orally. This shows that this class of formulation is the most popular worldwide and
the major attention of the researcher is towards this direction.
B) Multiple compressed tablets
• Compression coated tablet
• Layered tablet
• Delayed action tablet
• Floating tablet
• Colon targeting tablet
• Chewable tablet
• Dispersible tablet
•
C) Tablets used in the oral cavity
The tablets under this group are aimed release API in oral cavity or to provide local action in
this region. The tablets under this category avoids first-pass metabolism, decomposition in
gastric environment, nauseatic sensations and gives rapid onset of action.
• Lozenges and troches
• Buccal tablet Dental cones
• Mouth dissolved tablet
D) Tablets administered by other routes
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These tablets are administered by other route except for the oral cavity and so the drugs are
avoided from passing through gastro intestinal tract. These tablets may be inserted into other
body cavities or directly placed below the skin to be absorbed into systemic circulation from
the site of application.
• Vaginal tablet,  
• Implants
E) Tablets used to prepare solution
The tablets under this category are required to be dissolved first in water or other solvents
before  administration  or  application.  This  solution  may  be  for  ingestion  or  parenteral
application or for topical use depending upon type of medicament used
• Effervescent tablet
• Hypodermic tablet
1.7 FORMULATION OF TABLET31,32,33,34,35
                    Tablet generally consists of mixture of active pharmaceutical ingredient and
excipient. Excipient means any component other than the active pharmaceutical ingredient(s).
While  selecting  excipients  for  any  formulation  following  things  should  be  considered
wherever possible.
 Keep the excipients to a minimum in number
 Minimize the quantity of each excipients
 Multifunctional  excipients  may  be  given  preference  over  unifunctional
excipients.
1.7.1 Excipients are chosen in tablet formulation to perform a variety of functions like
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 For  providing essential  manufacturing technology functions  (binders,  glidants,
lubricants may be added)
 For enhancing patient acceptance (flavors, colorants may be added) 
 For providing aid in product identification (colorants may be added)
 For Optimizing or modifying drug release (disintegrants, hydrophilic polymers,
wetting agents,  biodegradable polymers may be added)
 For enhancing stability (antioxidant, UV absorbers may be added)
1.8) ROLE OF EXCIPIENTS IN SOLID DOSAGE FORM36
A) Diluents or Fillers
Diluents are added where the quantity of active ingredients is small or difficult to
compress. Eg: lactose, mannitol.
B) Binders or Granulating agents or Adhesive
Binders help powders fuse or link particles to another. Eg: starch, povidone.
C) Disintegrants
Disintegrants help the tablet break up after the patients ingest it. Eg: cross carmellose
sodium, starch.
D) Lubricants
Lubricants prevent powders from sticking to the metal component of the tablet press
and tablet press tooling. Eg: talc, aerosol.
E) Glidant
Glidants are agents that are added to the tablet formulation in order to improve the
flow property of the granulation. They act by reducing inter particulate friction. Eg:
Magnesium Stearate.
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F) Adsorbents
Adsorbents are the substances included in a formulation that are capable of holding
quantities of fluid in an apparently dry state. Oil soluble drugs, fluid extracts or oil
can be mixed with adsorbents and then granulated and compressed into the tablets.
Eg: fumed silica, microcrystalline cellulose, magnesium carbonate.
G) Colorants
Colorants are often added to tablet formulation to add value or for product 
identification.
1.9) TABLET MANUFACTURING PROCESS31,32,33,39
                             A tablet with good characterization is made in the granulation process.
Joined  particles  within  a  given  granulation  process  will  improve  flow  and  compression
characteristics,  reduce  segregation,  improve  content  uniformity,  and  eliminate  excessive
amount  of  fine  particles.  The  results  improve  yield,  reduced  tablet  defects,  increased
productivity and reduced down time. The objective of the process is to combine ingredients
to produce a quality tablet.
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Table No: 1 Steps Involved in Tablet Manufacturing Process
S.NO
PROCESSING
STEPS
DIRECT
COMPRESSION
WET
GRANULATION
DRY
GRANULATION
1
RAW
MATERIALS
YES YES YES
2 WEIGHING YES YES YES
3 SCREENING YES YES YES
4 MIXING YES YES YES
5 COMPRES YES NO YES
6 WET MASS NO YES NO
7 MILLING NO NO YES
8 DRYING NO YES NO
9 SHIFTING NO YES YES
10 MIXING NO YES YES
11 COMPRESSION NO YES YES
1.10) IMMEDIATE RELEASE TABLETS37,38
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Tablets can be designed for use as immediate release products or by suitable modifications of
the composition and manufacturing process can also be designed as modified release products
with many different potential release patterns. 
However for immediate release tablets, tablet disintegrants play an important role in ensuring
that the tablet matrix break up on contact with the fluid in the stomach to allow the release of
the active drug which then become available in whole or in part, for absorption from the
gastrointestinal tract (GIT). Although most drugs are absorbed from the GIT after passing
through the stomach, it is never the less important with immediate release products that the
tablets disintegrates properly in the stomach to release the drug and allow it to be absorbed
quickly after passing through the pyloric sphincter and on into duodenum and beyond.
1.11) BILAYERED TABLETS40,43
Dual release is a unit compressed tablet dosage form intended for oral application. It contains
two parts, in which one part is having conventional or immediate release part while the other
is sustained or controlled released part. In this chemically incompatible materials or those
which separate in a mixed granulation present in the same tablet. For sustained action of
products  each  layer  may  be  formulated  for  different  release  characteristics.  Sometimes
different drug formulated in a same tablet to achieve different pharmacological action from a
single tablet.
APPLICATIONS:
a) Used in the combination therapy and to deliver the loading dose a sustained dose of the
same or different drugs. 
b) Used for bilayer floating tablet in which one layer is floating layer and another one is
releases layer of the drug and to deliver tow different drugs having different releases profiles.
ADVANTAGES: 
a) Better product compliance, therapeutic efficacy and provide good efficiency.
b) Red/uced dosing intervals, number of dosing and number dosage forms.
c) Incompatible drugs are given by separating these drugs by inert materials.
1.12) STABILITY STUDIES AS PER ICH GUIDELINES41,44
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                                    Stability is defined as the capacity of a drug substance of a drug
product  to  remain  within  the  established  specifications  to  maintain  its  identity,  strength,
quality and purity throughout the retest or expiration dating period.
The objectives of stability of stability studies determine the shelf life, namely the time period
of storage at a specific condition within which the drug product still meets its established
specifications.
Stability is essential factor of quality, safety and efficacy of a drug product. A drug product,
which is not of sufficient stability results in changes in physical (like hardness, dissolution
rate,  phase  separation  etc)  as  well  as  chemical  characteristics  (formulation  of  high  risk
decomposition substances).
The chemical stability of drug is of great importance since it  becomes less effective as it
undergoes degradation. Also drug decomposition may yield toxic byproducts that are harmful
to patients. Microbiological instability of a sterile drug product could also be hazardous.
Stability valuation of drug substance is the key to drug quality as it determines the efficacy of
any drug or dosage forms. Stability assessment of drug products and drug substances are
mandated by regulatory agencies across the world.
In fact stability testing issues are responsible for a number of audit findings by regulatory
agencies.  Stability  testing  problems  are  regularly cited  in  warning  letters  and  sometimes
results in costly product recall.
Stability testing provides evidence that the quality of drug substance change with time under
the influence of various environmental conditions such as temperature, relative humidity etc.
Stability studies consist of a series of test in order to maintain an assurance of stability of
drug  product,  namely  maintenance  of  the  drug  product  packed  in  specified  packaging
material and stored in established storage condition within the determined time period
 AIM OF STUDY:
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Developing a new formula for bilayer tablet containing Acetaminophen and 
Methocarbamol, by Evaluation of trial products and Drug release profile. 
Stability testing alsoshould be done as per ICH guidelines.
 OBJECTIVE OF STUDY:
• To carry out literature survey of the drug molecules.
• Formulation of the tablets using different trials
• To analyse the trial samples.
• To optimize the final formula. 
3. PLAN OF WORK
 Development of final formula.
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• Literature collection of trial product.
• Pre formulation studies.
• Formulation of trial products.
• Dissolution studies of trials.
• Finalization of quantitative formula.
4. REVIEW OF LITERATURE:
• Remya P.N, Damodharan N, Sulakshan Kumar C.V et al (2010).,45  To develop a robust
formulation of Bi-layer tablets of Ibuprofen and Methocarbamol using Povidone k-30 as
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binder.  The basic  aim of  any Bi-layer  tablet  formulation  is  to  separate  physically or
chemically incompatible ingredients  and to produce repeat  action or prolonged action
tablet. The drug products may be developed to reduce Low back pain. The mechanism of
Methocarbamol is  a skeletal  muscle relaxant which acting centrally through inhibiting
inter neuronal activity and blocking polysynaptic reflex pathway at spinal card. Ibuprofen
is a pain relieving agent which inhibits the activity of Cyclooxygenase an enzyme crucial
for synthesis of prostaglandins. A total number of nine formulations have been taken to
optimize and develop a robust and stable formulation. Among the formulations tablets of
formulation F8 containing Ibuprofen 200mg and Methocarbamol 500mg per tablet was
taken  as  optimized  formula  due  to  its  higher  rate  of  dissolution  95.1  to  97.2% was
measure by taking  absorbance by HPLC technique.
• Mallikarjuna Reddy, N. K. Durga Devi*, B. R. Madhavi et al (2010).,46   simultaneous
determination  of  Acetaminophen  and  Methocarbamol  in  bilayered  tablet  dosage  form
formulated by RP-HPLC. A Develosil ODS-MG-5 column having 100×4.6mm internal
dimensions was used as stationary phase and Milli Q water, Methanol & Glacial acetic
acid in the ratio of 600:400:15 as mobile phase. The flow rate was 1.0ml/min & effluent
monitored  at  273nm.The  retention  times  of  Acetaminophen  &  Methocarbamol  were
found to be 1.846 and 4.713 min. respectively The linearity range for acetaminophen and
methocarbamol  was 75-600 and  50-400 µg/ml  with correlation  values  of  0.9998 and
0.999  respectively.  The  recovery  was  found  to  be  in  the  range  of  98.28-99.96% for
acetaminophen and 99.36-101.64% for methocarbamol.
 
• Deelip Derle*, Omkar Joshi, Ashish Pawar et al (2009).,47 The purpose of the study was
to  formulate  and  evaluate  mucoadhesive  bi-layer  buccal  tablets  of  propranolol
hydrochloride  tablets  using  the  bioadhesive  polymers  such  as  sodium  alginate  and
carbopol 971 P along with ethyl cellulose as an impermeable backing layer. The dose in
the formulation for fast release was 25 mg, the maintenance dose or sustained dose (55
mg) of propranolol hydrochloride. Tablets containing sodium alginate and carbopol 971 P
in the ratio  of  5:1 showed the  maximum percentage  of  in  vitro  drug release  without
disintegration  in  12  hoursby  UV  Double  beam  spectrophotometer  at  290  nm..  The
swelling index was proportional to sodium alginate content and inversely proportional to
carbopol 971 P content. The surface pH of all tablets was found to be satisfactory, closeto
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neutral pH; hence, no irritation would observe with these tablets. The mechanism of drug
release was found to be zero-order kinetics.
• N.N.Rajendran*, R.Natarajan, R. Subashini et al (2011).,48  The present study was to
establish and evaluate the  Bi‐layer tablets containing Metformin HCl as sustained release
and Pioglitazone HCl as immediate release layer. Sustained layer were prepared by wet
granulation method using different viscosity grade of HPMC (HPMC K4M & HPMC
K100M) as polymers and immediate release layer were prepared by direct compression
method using superdisintegrants  such  as  sodium starch  glycolate  and crosscarmellose
sodium. The result showed that combinations of polymers namely HPMC K100M and
HPMC K4M in  sustained  layer  can  control  the  release  of  drug.  The  in  vitro  release
profiles  of  drug  from  sustained  release  layer  could  be  best  expressed  by  Higuchi’s
equation as the plots showed high linearity (R2 >0.988) and diffusion was the dominant
mechanism of  drug release.  The formulations (P6M7) having immediate release layer
produces immediate effect within 54 second followed by sustained release (97.35%) at 8
hrs and it comparable with innovator.
• S.Jayaprakash, S. Mohamed Halith, K.Kulathuran Pilla et al (2011).,49  Bilayer tablets
of Amlodipine besilate (IR) Metoprolol succinate (SR) were formulated and evaluated for
the management of hypertension. In the formulation of immediate release sodium starch
glycolate  and  pregelatinised  starch  were  used  as  super  disintegrant  and  was  directly
compressed. For It was found that the optimized formulation showed 90.46% release for
Metoprolol  succinate  in  20  hours  respectively.However,  Amlodipine  besilate  released
98.28% at the end of 30 minutes.The IR spectrum and DSC studies revealed that there is
no disturbance in the principal peaks of pure drugs Metoprolol succinate and Amlodipine
besilate. The kinetic studies of the formulations revealed that diffusion is the predominant
mechanism of drug and release follows first order kinetics.
• Md.  Saleem  et  al  (2011).,50  has  done  the  validation  for  ibuprofen  200mg  &
methocarbamol  500mg  caplet  dosage  form.  Critical  parameters  involved  in  sifting,
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drymixing,  preparation  of  granulating agent,  wet  mixing,  wet  milling,  drying,  sizing,
lubrication, compression stages & coating were identified and evaluated.
• Dhaneshwar  shep  et.al  (2010).,51  studied  the  bioequivalence  and  pharmacokinetic
evaluation of two formulations of paracetamol ER 650mg accesing the pharmacokinetic
parameters Cmax, Tmax,T1/2, AUC0-t, AUC0-∞ and Kel and compared the bioequivalence range
and is found to be within the range 80% to 125%.
• Venkatesh radhakrishnan et.al (2011).,52  has studied the dissolution profile of bilayered
conventional  release  paracetamol  and  sustained  release  diclofenac  sodium,  for
simultaneous UV method determination and compared with the market product and they
are fitted to higuchi model.
• Kiran muscle  et.al  (2011).,53  has  donethe  formulation and development  of  bilayered
tablet of diclofenac as sustained release form using polyethylene glycol, microcrystalline
cellulose and crospovidone as independent variables for fabricating paracetamol tablets
diclofenac tablets prepared using HPMC as matrixing agent.
• Hosna  Banu  et.al  (2011)54 has  done  the  formulation  development  of  bilayered
acetaminophen tablets for extended release of drug with other being immediate release
layer tablets are prepared by wet granulation method using HPMC 15cps, HPMC 100cps,
K4MCR  as  release  rate  retardants  and  analyzer  for  zero  order,  first  order  Higuchi,
Kosmeyer, Peppas models for the release kinetics.
• MA Naeem et.al (2010)55  has formulated and evaluated controlled release bilayer tablets
containing micro encapsulated tramadol & acetaminophen. Micro particles are prepared
with  Ec  by  coacervation  by  temperature  change  method  and  micro  particles  are
compressed in to bilayered tablets and evaluated by FTIR, XRD, DSC, TGA and drug
release kinetic studies.
5. DRUG AND EXCIPIENTS PROFILE:
5.1 DRUG PROFILE:
5.1.1 ACETAMINOPHEN DRUG PROFILE12,13,14
Figure No: 1 Structural Formula
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Table No: 2 Acetaminophen Drug Profile
Properties Information
Molecular Formula C8H9NO2
Molecular weight 151.16
IUPAC name N-(4-hydroxyphenyl)acetamide
Macroscopic Appearance White, crystalline powder
Half-life 1 to 4 hours
Solubility Slightly soluble in Water,
Soluble in Organic solvents. 
PH Stable at a pH between 4 and 7 at 25°C.
Pka 9.51 at 25°C.
Use Analgesics, Non-Narcotic, antipyretics
Mechanism of Action
Analgesia15,16,17,18,24
Although  the  exact  site  and  mechanism  of  analgesic  action  is  not  clearly  defined,
acetaminophen appears to produce analgesia by elevation of the pain threshold. The potential
mechanism may involve  inhibition  of  the  nitric  oxide  pathway mediated  by a  variety of
neurotransmitter receptors including N-methyl-D-aspartate and substance P.
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Antipyretic19,20,21,25,27
Investigations indicate that endogenous pyrogens produced by leukocytes cause an elevation
of prostaglandin E (PGE) in the cerebrospinal fluid. Fever results when the elevated PGE acts
on the pre optic area of the anterior hypothalamus to decrease heat loss and increase heat
gain. Acetaminophen has been shown to inhibit the action of endogenous pyrogens on the
heat-regulating centers in the brain by blocking the formation and release of prostaglandins in
the central nervous system. Inhibition of arachidonic acid metabolism is not requisite for the
antipyretic effect of acetaminophen. Acetaminophen does not depend upon the activation of
the arginine vasopressin V-1 receptor to induce antipyresis as has been noted in rats treated
with indomethacin and salicylates. This has been demonstrated in animals by observing a
decrease  in  both  fever  and  PGE  activity  following  administration  of  acetaminophen  to
unanesthetized  cats,  and  in  rabbits  and  dogs  when  brain  prostaglandin  synthetase  was
inhibited by the administration of acetaminophen.
5.1.2 METHOCARBAMOL DRUG PROFILE 29
Figure No: 2 Structural Formula of Methocarbamol
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Table No: 3 Methocarbamol Drug Profile
Properties Information 
Molecular Formula C11H15NO5 
Molecular weight 241.24 
IUPAC name 3-(2-methoxyphenoxy)-1,2-propanediol  1-
carbamate. 
Macroscopic Appearance White, crystalline powder.
Half-life 1-2 hours
Solubility Sparingly soluble in Water
PH Stable at a pH between 4 and 7 at 25°C. 
Pka 9.51 at 25°C.
Use Anti-inflammatory, skeletal muscle relaxant 
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Mechanism of Action29
                      Methocarbamol is thought to act primarily in the CNS, increasing the pain
threshold  by  inhibiting  both  isoforms  of  cyclooxygenase,  COX-1,  COX-2,  and  COX-3
enzymes involved in prostaglandin (PG) synthesis. Unlike NSAIDs, Methocarbamol does not
inhibit cyclooxygenase in peripheral tissues and, thus, has no peripheral anti-inflammatory
affects.  While  aspirin  acts  as  an  irreversible  inhibitor  of  COX  and  directly  blocks  the
enzyme's active site, studies have found that methocarbamol  indirectly blocks COX, and that
this  blockade  is  ineffective  in  the  presence  of  peroxides.  This  might  explain  why
acetaminophen is effective in the central nervous system and in endothelial cells but not in
platelets  and immune cells  which have high levels of peroxides.  Studies  also report  data
suggesting  that  methocarbamol  selectively  blocks  a  variant  of  the  COX enzyme  that  is
different from the known variants COX-1 and COX-2. This enzyme is now referred to as
COX-3. Its  exact mechanism of action is still  poorly understood, but future research may
provide further insight into how it works.
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   5.2 EXCIPIENTS PROFILE
POVIDONE37,38
Table No: 4 Povidone excipients Profile
Non-proprietary
Names
 • BP: Povidone, JP: Povidone, PhEur: Povidonum USP: Povidone
Synonyms
E1201;  Kollidon;  Plasdone;  poly[1-(2-oxo-1-
pyrrolidinyl)ethylene]; polyvidone; polyvinylpyrrolidone; PVP; 1-
vinyl-2-pyrrolidinone polymer
Empirical
formula
(C6H9NO)n
Molecular
weight
2500–3 000 000
Description
Povidone  occurs  as  a  fine,  white  to  creamy-white  colored,
odorless or almost odorless, hygroscopic powder. 
Functional
categories
Disintegrant; dissolution aid; suspending agent; tablet binder.
Solubility
freely  soluble  in  acids,  chloroform,  ethanol  (95%),  ketones,
methanol, and water; 
Melting point Softens at 150°C.
Stability  and
storage
Povidone  may  be  stored  under  ordinary  conditions  without
undergoing  decomposition  or  degradation.  However,  since  the
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conditions
powder is hygroscopic, it should be stored in an airtight container
in a cool, dry place.
Incompatibilities
It forms molecular adducts in solution with sulfathiazole, sodium
salicylate,  salicylic  acid,  phenobarbital,  tannin,  and  other
compounds.
Applications
Povidone solutions may also be used as coating agents and it is
also  used  as  a  suspending,  stabilizing,  or  viscosity-increasing
agent In tableting, povidone solutions are used as binders in wet-
granulation.
 MICROCRYSTALLINE CELLULOSE38
Table No: 5 Microcrystalline cellulose excipients Profile
Non-proprietary
Names
• BP: Microcrystalline cellulose, 
• PhEur: Cellulosemmicrocristallinum, 
• JP: Microcrystalline cellulose,
• USPNF: Microcrystallinecellulose
Synonyms
Avicel  PH;  Cellets;  Celex;  cellulose  gel;
hellulosummicrocristallinum;  Celphere;  Ceolus  KG;  crystalline
cellulose;  E460;  Emcocel;  Ethispheres;  Fibrocel;  MCC  Sanaq;
Pharmacel; Tabulose; Vivapur.
Empirical
formula
(C6H10O 5)n where n~220
Molecular
weight
3600 g/mol.
Description MCC occurs  as  a  white,  odourless,  tasteless,  crystalline powder
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composed of porous particle.
Functional
categories
Adsorbent;  suspending  agent;  tablet  and  capsule  diluent;  tablet
disintegrant
Solubility
Slightly soluble in 5% w/v sodium hydroxide solution; practically
insoluble in water, dilute acids, and most organic solvents.
Melting point 260-270oC
Stability  and
storage
conditions
Microcrystalline cellulose is a stable though hygroscopic material.
The bulk material should be stored in a well-closed container in a
cool, dry place
Incompatibilitie
s
Microcrystalline  cellulose  is  incompatible  with  strong  oxidizing
agents
Applications
Microcrystalline  cellulose  is  widely  used  primarily  as  a
binder/diluent in oral tablet and capsule formulations where it is
used  in  both  wet-granulation  and  direct  compression  processes.
Also as lubricant and disintegrant 
MAGNESIUM STEARATE37
Table No: 6 Magnesium Stearate excipients Profile
Non-proprietary
Names
BP: Magnesium Stearate, JP: Magnesium Stearate ,PhEur: Magnesium
Stearate ,
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Synonyms
Dibasic  magnesium stearate;  magnesium distearate;  magnesiistearas;
magnesium octadecanoate; octadecanoic acid, magnesium salt; stearic
acid, magnesium salt; Synpro 90
Empirical
formula C36H70MgO4
Molecular weight 591.24
Description
Magnesium stearate is a very fine, light white, precipitated or milled,
impalpable powder of low bulk density, having a faint odor of stearic
acid and a characteristic taste. The powder is greasy to the touch and
readily adheres to the skin.
Functional 
Categories
Tablet and capsule lubricant.
Solubility Practically  insoluble  in  ethanol,  ethanol  (95%),  ether  and  water;
slightly soluble in warm benzene and warm ethanol (95%).
Melting point 117–150 oC
Stability  and
storage
conditions
Magnesium stearate  is  stable and  should be stored in  a  well-closed
container in a cool, dry place.
Incompatibilities Incompatible with strong acids, alkalis, and iron salts. Avoid mixing
with strong oxidizing materials.
Applications It is primarily used as a lubricant in capsule and tablet manufacture.
 STEARIC ACID38
Table No: 7 Stearic Acid excipients Profile
Octadecanoic acid
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Non-proprietary
Names
Synonyms C18:0 (lipid number)
Empirical
formula
C18H36O2
Molecular
weight
284.48 g/mol.
Description
Stearic acid is  a hard white or faintly yellow – colored, somewhat
glossy, crystalline solid or a white or yellowish white powder. It has a
slight odour and taste suggesting tallow.
Functional
categories
Emulsifying agent, solubilizing agent, tablet and capsule lubricant
Solubility
Freely soluble in benzene, carbon tetrachloride, chloroform and ether.
Soluble in ethanol (95%), hexane and propylene glycol. Practically
insoluble in water
Melting point 69.6oC
Stability  and
storage
conditions
Stearic acid is a stable material. An antioxidant may also be added to
it. The bulk material should be stored in a well – closed container in a
cool, dry place.
Incompatibilitie
s
Stearic acid is incompatible with most metal hydroxides and may be
incompatible with oxidizing agents.
Applications It aids dispersion of pigments and fillers.
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It acts as a stock lubricant
PRE GELATINIZED STARCH38
Table No: 8 Pre Gelatinized Starch excipients Profile
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Non-proprietary
Names
Amylum, polysaccharide
Synonyms Starch 1500, starch LM
Empirical
formula
(C6H10O5)n
Molecular
weight
Depends on extent of gelatinization
Description White color, odourless, tasteless
Functional 
Categories
Thickening agent,  stiffening or gluing agent
Solubility
Insoluble in cold water or alcohol, Becomes soluble in water on
heating
Stability  and
storage
conditions
Starch is stable and should be stored in a well-closed container in a
cool, dry place.
Incompatibilities
Incompatible with strong acids, alkali.  Avoid mixing with strong
oxidizing materials.
Applications Binder, Disintegrant, flow aid, lubricant.
SODIUM LAURYL SULPHATE38
Table No: 9 Sodium Lauryl Sulphate excipients Profile
Non-proprietary
Names
Sodium dodecyl sulfate (SDS or NaDS), sodium laurilsulfate 
Synonyms
Sodium  monododecyl  sulfate;  Sodium  lauryl  sulfate;  Sodium
monolauryl  sulfate;  Sodium  dodecanesulfate;  dodecyl  alcohol,
hydrogen sulfate,  sodium salt;  n-dodecyl  sulfate sodium; Sulfuric
acid monododecyl ester sodium salt
Empirical
formula
NaC12H25SO4
Molecular
weight
288.38 g mol−1
Description
 It  is  an anionic surfactant used  in  many  cleaning  and  hygiene
products. The salt is of an organosulfate consisting of a 12-carbon
tail  attached  to  a sulfate group,  giving  the  material
the amphiphilic properties required of a detergent.
Functional
categories
Surfactant  to  remove  oil  stains,   aid  in lysing cells during DNA
extraction
Solubility
Slightly soluble in 5% w/v sodium hydroxide solution; practically
insoluble in water, dilute acids, and most organic solvents.
Melting point 206oC
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Stability  and
storage
conditions
The bulk material should be stored in a well-closed container in a
cool, dry place
Incompatibilitie
s
Sodium  lauryl  sulphate   is  incompatible  with  strong  oxidizing
agents
Applications
found  in toothpastes, shampoos, shaving  foams,  and bubble
bath formulations in part for its thickening effect and its ability to
create a lather
SODIUM STARCH GLYCOLATE37
Table No: 10 Sodium Starch Glycolate excipients Profile
Non-proprietary
Names
Explotab, vivastar
Synonyms Sodium salt of carboxymethyl ether of starch
Empirical
formula
C2H5ONa
Molecular
weight
500000 – 11000000
Description
White  to  off-white,  tasteless,  odorless,  relatively  free  flowing
powder.
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Functional
categories
Disintegrant, Dissolution aid, Suspending agent
Solubility Practically insoluble in organic solvents. Absorbs water rapidly.
Melting point ⁰338 C
Stability  and
storage
conditions
Store in well closed container to protect from humidity
Incompatibilitie
s
Mostly compatible with all other tableting ingredients
Applications Suspending and gelling agent
COLLOIDAL SILICON DIOXIDE38
Table No: 11 Colloidal Silicon Dioxide excipients Profile
Non-proprietary
Names
 Aerosil, cab-o-sil
Synonyms Silica gel, silica sols, precipitated silica
Empirical
formula
Polymer with multiple units of Si(OH)4
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Molecular
weight
Depends on length of polymer chain
Description
Mono  disperse  or  poly  disperse  suspension  with  particle  size
ranging from 30 to 100 nm
Functional
categories
Glidant, Binder, catalyst, moisture absorption
Solubility
Practically  insoluble  in  water,  dilute  acids,  and  most  organic
solvents.
Melting point 1600 - 1725oC
Stability  and
storage
conditions
Colloidal solution is stabilized by pH adjustment and concentrated
by evaporation
Incompatibilitie
s
Incompatible with strong oxidizing agents
Applications Flow promoter, glidant, lubricant
6. METHODOLOGY
6.1 PRE-FORMULATION STUDIES
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 Pre-formulation testing is  an investigation of physical  and chemical properties of a drug
substance  alone  and  when  combined  with  excipients.  It  is  the  first  step  in  the  rational
development of dosage forms. 
A) Physiochemical evaluation of drug molecule:
1) Description. 
2) Solubility. 
3) pH. 
4) Melting point. 
5) Chemical nature. 
6) Hygroscopicity. 
7) Loss on drying. 
8) Particle size determination. 
9) Flow properties. 
B) Compatibility Studies of the Drug with Excipients: 
                       The information obtained from Preformulation studies indicates many of the
subsequent  events  and  approaches  to  be  taken  into  consideration  during  formulation
development. 
A) PHYSIOCHEMICAL PARAMETERS35,37,42:
1) Description
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It is the initial evaluation during Preformulation studies which assess the color and odor
of the substance. This was only a descriptive test.
2) Solubility
Acetaminophen is classified under class III according to BCS i.e; highly soluble but low 
permeable. Methocarbamol is class II drug with low solubility and good permeability 
Solubility studies were conducted at all pH ranges from 1 to 7.4. The solubility of API was 
determined by dissolving the highest unit dose of the drug in 250 mL of buffer adjusted 
between pH 1.0 and 7.4. For this purpose 0.1N HCl, pH 4.5 acetate  buffer, pH 6.8 phosphate 
buffer and Purified water were used. Highest dose of the drug i.e., 500mg was dissolved in 
250 mL of medium and was kept untouched for 12 hrs. Later on the insoluble drug was 
filtered off and the solution was analysed by HPLC technique to find out the solubility.
3) pH: 
The pH is the measure of negative logarithm of hydrogen ion concentration of an aqueous
solution. It  is one of the most important factors from which the stand point of solubility,
stability  and  physiochemical  suitability  of  a  formulation.  The  pH value  of  a  solution  is
determined potentiometrically by means of a glass electrode.
4) Melting point
The temperature at which the first particle of the substance completely melts is regarded as
melting point of the substance. The temperature at which the first particle starts to melt and
last particle completely melts is regarded as the melting range. 
5) Chemical nature
Solubility, stability, bioavailability etc., of a substance is depends on its chemical nature and
this information helps to design a suitable dosage form. 
6) Hygroscopicity 
It is defined as ability of a substance to absorb moisture from the environment it exposed.
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Table No: 12 Moisture Absorption Analysis
S.No NATURE OF
SAMPLE
RESULT OF THE DETERMINATION.
1 Deliquescent Sufficient water absorbed to form a liquid.
2 Very hygroscopic Increases in mass equal to or more than 15%.
3 Hygroscopic Increases in mass less than 15% and equal to or more
than 2%.
4 Slightly hygroscopic Increases in mass less than 2% and equal to or more
than 0.2%.
7) Loss on drying
0.5g of sample of was accurately weighed and the powder was kept in a moisture balance
⁰apparatus for 5 min. at 106 C and the moisture content was calculated.
8) Particle size determination
Grain Size Determination
Particle size distribution is an important factor which determines number of parameters like
dissolution rate, bioavailability, content uniformity, flow properties, texture and stability of a
formulation.  The  particle  size  can  be  analyzed  by  number  of  methods  like  sieving,
microscopic,  laser  diffraction  methods  etc,  the  particle  size  of  Atorvastatin  calcium  and
nicotinic acid was done by sieving method. 
Sieve analysis: 
Table No: 13 Classification of Sample Based on The % of Sample Retained or Passed on 
Test Sieves. 
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S.No NATURE OF SAMPLE RESULT OF DETERMINATION
1 Coarse powder NLT 95% of the sample mass pass through 14#
and NMT 40% pass through 36#
2 Moderately coarse powder NLT 95% of the sample mass pass through 25#
and NMT 40% pass through 60#
3 Moderately fine powder NLT 95% of the sample mass pass through 36#
and NMT 40% pass through 100#
4 fine powder NLT 95% of the sample mass pass through 
100# and NMT 40% pass through 150#
5 Very fine powder NLT 95% of the sample mass pass through 
150# and NMT 40% pass through 200#
6 Super fine powder NLT 90% by number of particle are less than 
10µm
9) Flow Property Measurement:
It is a very important parameter to be measured, since it affects the mass of uniformity of the
dose. It is usually predicted in terms of angle of repose, bulk density and tapped density.
Angle of Repose
The angle of repose has been used to characterize the flow properties of solids. Angle of
repose  is  a  characteristic  related  to  inter  particulate  friction  or  resistance  to  movement
between particles. This is the maximum angle possible between surface of pile of powder or
granules and the horizontal plane. 
 = Tan –1 h / r
Where
θ = angle of repose, 
h = height,
 r = radius.
A funnel was fixed at a height approximately of 2-4 cm over the platform. The loose
powder was slowly passed along the wall  of  funnel,  till  the cone of the powder formed.
Determine the angle of repose by measuring the height of the cone of powder and radius of
the heap of powder.
Table No: 14 Flow Properties and corresponding angle of repose
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FLOW PROPERTY ANGLE OF REPOSE 
(DEGREES) 
1 Excellent 25-30
2 Good 31-35
3 Fair 36-40
4 Passable 41-45
5 Poor 46-55
6 Very Poor 56-65
7 Very Very Poor > 66
Bulk Density (BD) and Tapped Density (TD)
Bulk density of a compound varies substantially with the method of crystallisation,
milling or formulation. It is of great importance when one considers the size of a high – dose
capsule  product  or  the  homogeneity of  a  low dose  formulation  in  which  there  are  large
differences  in  drug  and  excipient  densities.  In  addition  to  bulk  density,  it  is  frequently
desirable to know the true density of a powder for computation of void volume or porosity of
packed powder beds. 
An accurately weighed quantity of the granules/ powder was carefully poured into the
graduated cylinder and volume was measured. Then the graduated cylinder was closed with
lid and set into the tap density tester (USP). The density apparatus was set for 500 taps and
after that the volume was measured and continued operation till the two consecutive readings
were equal.  The bulk density and the tapped density were calculated using the following
formulae. 
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Bulk density = weight of sample in gram /volume occupied by the sample
Tapped density = Wt. of sample in gm / Tapped volume
S.No
Compressibility Index (CI) and Hausner ratio (HR)
The compressibility index and Hausner ratio methods are used for predicting
powder  flow characteristics.  Both  the  compressibility  index  and  the  Hausner  ratio  were
determined by using bulk density and the tapped density of a powder. 
Table No: 15 Relation of flow property with Hausners ratio & Compressibility Index
6.2 MATERIALS AND EQUIPMENTS
Table No: 16 List of materials for preparation of Acetaminophen
S.No. Name of Materials used Specification Use
1. Acetaminophen IP Active Ingredient
2. Microcrystalline Cellulose IP Diluent
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C.I=tapped-untapped*100/tapped
H.R=tapped density/bulk density.
3 Pre gelatinized Starch IP Dry Binder
4. Povidone K30 USP/NF Binder
5. Stearic acid IP Lubricant
6. Sodium starch glycolate USP/NF Super disintegrant
7. Purified Water IP Solvent 
Table No: 17 List of materials for preparation of Methocarbamol
Table No: 18 List of Equipments used for formulation of tablets
S.No. INSTRUMENTS USED MANUFACTURER
1. Electronic weighing balance, 210gm Mettler, Bangalore
2. Electronic weighing balance, 1 kg Mettler, Bangalore
3 Sifter 
Neomachine,  Calcutta,
India.
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S.No. Name of Materials used Specification Use
1. Methocarbamol IP
Active
Ingredient
2. Microcrystalline Cellulose IP Diluent
3 Pre gelatinized starch USP/NF Dry binder
4. Povidone k30  USP/NF Binder
5. Sodium lauryl sulphate IP Surfactant
5. Colloidal Silicon dioxide   IP Glidant 
6. Magnesium Stearate           IP Lubricant
7. Colour lake of sunset yellow  IH Coloring agent 
8. F D & C Blue IH Coloring agent
4. Rapid mixture granulator Tapasya, Mumbai, India
5. Fluidized bed dryer Tapasya, Mumbai, India
6. Multi mill
Neomachine,  Calcutta,
India
7. Blender Vamp, India
8. Tablet compression machine 16 station single rotary Cadmach, Ahmedabad
9. Automatic tablet dissolution apparatus USP II vanket, USA
10 Electronic thickness measurement apparatus Mituoyo, japan
11 Friability tester Electrolab, Mumbai, India)
12 Tablet hardness tester Schleuniger, USA
13 Electronic LOD measurement apparatus Sartorius, Germany
14 Bulk density apparatus Electrolab, Mumbai, India
15 HPLC Shimadzu ,Mumbai, India
16 FT-IR spectrophotometer Shimadzu, Mumbai, India
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6.3 PROCESS INVOLVED IN BI-LAYER TABLET PRODUCTION
Figure No: 3 Flow Chart process involved in bi-layer tablet production
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Drug Excipient
 Weighing & Sieving
Mixing
Binder preparation
Wet Granulation
Drying
Sifting and milling
Lubrication
Compression
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Steps Involved in Formulation of Methocarbamol granules
Take 54kg of water (temp 65ºC) in 100L stainless steel vessel. Then dissolve 0.72kg of 
povidone k-30 by stirring with stainless steel paddle. Then add D & C yellow ≠ 10 of 0.019kg
and F D & C blue # 1 of 0.0075kg. then disperse Sodium laurel sulfate 0.240 in 5kg of water 
separately in small vessel and add to above povidone solution slowly.
Dry mixing: - Check weight of methocarbamol and sift through 12# mesh and sift pre-
gelatinized starch and methyl cellulose through 40# mesh load in to rapid mixer granulation. 
Dry mix for 10min at low speed.
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Granulation:-  Add binder solution to above powder which mixing for 5-10min at mill slow 
speed. Change mill speed to fast and mix for 5-15min till required end point achieved. If 
required add up to 4kg additional water through rapid mixer granulation man hole. Switch 
granulator at fast speed and mix for 1-2min. pass the wet mass through co-mill attached to 
rapid mixer granulation while mixer at deep speed and granulator at slow speed. And unload 
into Fluidized bed dryer bowl. Scrap material from rapid mixer granulation bowl and 
Fluidized bed dryer bowl at end of batch. Record additional water quantity and record 
ampelage achieved on.
Drying :- Dry the wet milled granules in Fluidized bed dryer for 10min.Rake and check for 
loss on drying carry on drying for 10min and rake again. Dry till loss on drying at 0.6 - 1.2% 
achieved. Check loss on drying at 90ºC in halogen moisture balance.
Sifting and Dry mixing: - Pass the dried granules into double vibratory sifter. Collect the 
good fraction of granules passing through # 14/150 mesh through metal detector loads the 
granules and fines into the octagonal blender. Mill the sieve tops retained over # 14 mesh 
through 2.0mm screen using comminuting mill, knives forward and medium speed. Pass the 
miller granule through # 14 on double deck sifter. Collect all the granules passing through 
#14 through metal detector and load the granules into the octagonal blender.
Blending: - Load the granules in octagonal blender and blend for 5min at 6rpm. Add sifter 
sodium starch glycolate, micro crystalline cellulose, colloidal silicon through #40 mesh to 
octagonal blender. Add sifted magnesium stearate through #40 mesh to octagonal blender and
blend for 5min at 6rpm.
6.4  Formulation  Development  Comparative  data  of  various  formulations  of
Methocarbamol
Trial-1
Table No: 19 Formula of Methocarbamol Trial-1
S. No Ingredients Quantity
1 Methocarbamol 332mg
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2 Pregelatinised starch 16.1mg
3 Microcrystalline cellulose 20mg
4 PVP K 30 1.6mg
5 D&C yellow#10 0.02mg
6 FD&C Blue#2 0.3mg
7 Ferric oxide red 0.4mg
8 Micro crystalline cellulose 14.7mg
9 Sodium starch glycolate 12mg
10 Colloidal silicon di oxide 0.48mg
11 Magnesium stearate 2.4mg
Total % composition 400mg
Trial-2
Table No: 20 Formula of Methocarbamol Trial-2
S. No Ingredients Quantity
1 Methocarbamol 332mg
2 Pregelatinised starch 15.7mg
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3 Microcrystalline cellulose 20mg
4 PVP K 30 2mg
5 D&C yellow#10 0.02mg
6 FD&C Blue#2 0.3mg
7 Ferric oxide red 0.4mg
8 Micro crystalline cellulose 14.7mg
9 Sodium starch glycolate 12mg
10 Colloidal silicon di oxide 0.48mg
11 Magnesium stearate 2.4mg
Total % composition 400mg
Trial-3
Table No: 21 Formula of Methocarbamol Trial-3
S. No Ingredients Quantity
1 Methocarbamol 332mg
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2 Pregelatinised starch 14.6mg
3 Microcrystalline cellulose 20mg
4 PVP K 30 1.6mg
5 D&C yellow#10 0.02mg
6 FD&C Blue#2 0.8mg
7 Ferric oxide red 1.4mg
8 Micro crystalline cellulose 14.7mg
9 Sodium starch glycolate 12mg
10 Colloidal silicon di oxide 0.48mg
11 Magnesium stearate 2.4mg
Total % composition 400mg
Trial-4
Table No: 22 Formula of Methocarbamol Trial-4
S. No Ingredients Quantity
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1 Methocarbamol 332mg
2 Pregelatinised starch 14mg
3 Microcrystalline cellulose 20mg
4 PVP K 30 1.6mg
5 D&C yellow#10 0.02mg
6 FD&C Blue#2 1mg
7 Ferric oxide red 1.8mg
8 Micro crystalline cellulose 14.7mg
9 Sodium starch glycolate 12mg
10 Colloidal silicon di oxide 0.48mg
11 Magnesium stearate 2.4mg
Total % composition 400mg
Trial-5
Table No: 23 Formula of Methocarbamol Trial-5
S. No Ingredients Quantity
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1 Methocarbamol 332mg
2 Pregelatinised starch 14.6mg
3 Microcrystalline cellulose 20mg
4 PVP K 30 1.6mg
5 D&C yellow#10 0.02mg
6 FD&C Blue#2 1mg
7 Ferric oxide red 1.2mg
8 Micro crystalline cellulose 14.7mg
9 Sodium starch glycolate 12mg
10 Colloidal silicon di oxide 0.48mg
11 Magnesium stearate 2.4mg
Total % composition 400mg
Trial-6
Table No: 24 Formula of Methocarbamol Trial-6
S. No Ingredients Quantity
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1 Methocarbamol 332mg
2 Pregelatinised starch 14.4mg
3 Microcrystalline cellulose 20mg
4 PVP K 30 1.6mg
5 D&C yellow#10 0.02mg
6 FD&C Blue#2 1mg
7 Ferric oxide red 1.2mg
8 Sodium lauryl sulphate 0.2mg
9 Micro crystalline cellulose 14.7mg
10 Sodium starch glycolate 12mg
11 Colloidal silicon di oxide 0.48mg
12 Magnesium stearate 2.4mg
Total % composition 400mg
Trial-7
Table No: 25 Formula of Methocarbamol Trial-7
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S. No Ingredients Quantity
1 Methocarbamol 332mg
2 Pregelatinised starch 14.2mg
3 Microcrystalline cellulose 20mg
4 PVP K 30 1.6mg
5 D&C yellow#10 0.02
6 FD&C Blue#2 1mg
7 Ferric oxide red 1.2mg
8 Sodium lauryl sulphate 0.4mg
9 Micro crystalline cellulose 14.7mg
10 Sodium starch glycolate 12mg
11 Colloidal silicon di oxide 0.48mg
12 Magnesium stearate 2.4mg
Total % composition 400mg
Trial-8
Table No: 26 Formula of Methocarbamol Trial-8
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S. No Ingredients Quantity
1 Methocarbamol 332mg
2 Pregelatinised starch 13.8mg
3 Microcrystalline cellulose 20mg
4 PVP K 30 1.6mg
5 D&C yellow#10 0.02mg
6 FD&C Blue#2 1mg
7 Ferric oxide red 1.2mg
8 Sodium lauryl sulphate 0.8mg
9 Micro crystalline cellulose 14.7mg
10 Sodium starch glycolate 12mg
11 Colloidal silicon di oxide 0.48mg
12 Magnesium stearate 2.4mg
Total % composition 400mg
Trial-9
Table No: 27 Formula of Methocarbamol Trial-9
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S. No Ingredients Quantity
1 Methocarbamol 332mg
2 Pregelatinised starch 13.8mg
3 Microcrystalline cellulose 20mg
4 PVP K 30 1.6mg
5 D&C yellow#10 0.02mg
6 FD&C Blue#2 1mg
7 Ferric oxide red 1.2mg
8 Sodium lauryl sulphate 0.8mg
9 Micro crystalline cellulose 14.7mg
10 Sodium starch glycolate 12mg
11 Colloidal silicon di oxide 0.48mg
12 Magnesium stearate 2.4mg
Total % composition 400mg
Steps Involved in Formulation of Acetaminophen granules
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Take 54kg of water (temp 65ºC) in 100L stainless steel vessel. Then dissolve 0.72kg of 
povidone k-30 by stirring with stainless steel paddle. then disperse sodium starch glycolate 
0.240 in 5kg of water separately in small vessel and add to above povidone solution slowly.
Dry mixing: - check weight of acetaminophen and sift through 12# mesh and sift pre-
gelatinized starch and methyl cellulose through 40# mesh load in to rapid mixer granulation. 
Dry mix for 10min at low speed.
Granulation:- Add binder solution to above powder which mixing for 5-10min at mill slow 
speed. Change mill speed to fast and mix for 5-15min till required end point achieved. If 
required add up to 4kg additional water through rapid mixer granulation man hole. Switch 
granulator at fast speed and mix for 1-2min. pass the wet mass through co-mill attached to 
rapid mixer granulation while mixer at deep speed and granulator at slow speed. And unload 
into Fluidized bed dryer bowl. Scrap material from rapid mixer granulation bowl and 
Fluidized bed dryer bowl at end of batch. Record additional water quantity and record 
ampelage achieved on.
Drying:- Dry the wet milled granules in Fluidized bed dryer for 10min.Rake and check for 
loss on drying carry on drying for 10min and rake again. Dry till loss on drying at 0.6 - 1.2% 
achieved. Check loss on drying at 90ºC in halogen moisture balance.
Sifting and Dry mixing: - Pass the dried granules into double vibratory sifter. Collect the 
good fraction of granules passing through # 14/150 mesh through metal detector loads the 
granules and fines into the octagonal blender. Mill the sieve tops retained over # 14 mesh 
through 2.0mm screen using comminuting mill, knives forward and medium speed.
Pass the miller granule through # 14 on double deck sifter. Collect all the granules passing 
through #14 through metal detector and load the granules into the octagonal blender.
Blending: - Load the granules in octagonal blender and blend for 5min at 6rpm. Add sifter 
sodium starch glycolate, micro crystalline cellulose, colloidal silicon through #40 mesh to 
octagonal blender. Add sifted stearic acid through #40 mesh to octagonal blender and blend 
for 5min at 6rpm.
6.5 Comparative data of various formulations of Acetaminophen
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Trial-1
Table No: 28 Formula of Acetaminophen Trial-1
S. No Ingredients Quantity
1 Acetaminophen 450mg
2 Microcrystalline cellulose 32.5mg
3 PVP K 30 5mg
4 Stearic acid 5mg
5 Total 500mg
Trial-2
Table No: 29 Formula of Acetaminophen Trial-2
S. No Ingredients Quantity
1 Acetaminophen 450mg
2 Microcrystalline cellulose 40mg
3 PVP K 30 5mg
4 Sodium starch glycolate 7.5mg
5 Stearic acid 5mg
6 Total 500mg
Trial-3
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Table No: 30 Formula of Acetaminophen Trial-3
S. No Ingredients Quantity
1 Acetaminophen 450mg
2 Microcrystalline cellulose 30mg
3 PVP K 30 5mg
4 Sodium starch glycolate 10mg
5 Stearic acid 5mg
6 Total 500mg
Trial-4
Table No: 31 Formula of Acetaminophen Trial-4
S. No Ingredients Quantity
1 Acetaminophen 450mg
2 Microcrystalline cellulose 30mg
3 PVP K 30 5mg
4 Sodium starch glycolate 10mg
5 Stearic acid 5mg
6 Total 500mg
Trial-5
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Table No: 32 Formula of Acetaminophen Trial-5
S. No Ingredients Quantity
1 Acetaminophen 450mg
2 Pregelatinised starch 2.5mg
3 Microcrystalline cellulose 30mg
4 PVP K 30 2.5mg
5 Sodium starch glycolate 10mg
6 Stearic acid 5mg
7 Total 500mg
Trial-6
Table No: 33 Formula of Acetaminophen Trial-6
S. No Ingredients Quantity
1 Acetaminophen 450mg
2 Pregelatinised starch 10mg
3 Microcrystalline cellulose 22.5mg
4 PVP K 30 2.5mg
5 Sodium starch glycolate 10mg
6 Stearic acid 5mg
7 Total 500mg
Trial-7
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Table No: 34 Formula of Acetaminophen Trial-7
S. No Ingredients Quantity
1 Acetaminophen 450mg
2 Pregelatinised starch 20mg
3 Microcrystalline cellulose 12.5mg
4 PVP K 30 2.5mg
5 Sodium starch glycolate 10mg
6 Stearic acid 5mg
7 Total 500mg
Trial-8
Table No: 35 Formula of Acetaminophen Trial-8
S. No Ingredients Quantity
1 Acetaminophen 450mg
2 Pregelatinised starch 29.5mg
3 PVP K 30 2.5mg
4 Sodium starch glycolate 10mg
5 Stearic acid 8mg
6 Total 500mg
Trial-9
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Table No: 36 Formula of Acetaminophen Trial-9
S. No Ingredients Quantity
1 Acetaminophen 450mg
2 Pregelatinised starch 29.5mg
3 PVP K 30 3mg
4 Sodium starch glycolate 7.5mg
5 Stearic acid 10mg
6 Total 500mg
Moisture content: - [by karl fisher method]
Transfer 35-40ml of methanol to the titration vessel and titrate with the reagent to the 
electrometric or visual end point to consume any moisture that may be present. Grind 10tabs 
to a fine powder in dry mortar. Weigh accurately between 0.2-0.5gm of powdered sample, 
and quickly add to the titration vessel and perform the test potentiometrically.
6.6 COMPRESSION OF BI LAYER TABLETS:
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6.6.1 Compression Parameters:-
Compression is done by using SEJONG 49 station compression machine specially designed
for the compression of bi layer tablets having two different hoppers for the flow of granules
of two drugs.Two punches are set in the compression machine for the compression of two
layers.  First acetaminophen layer undergoes slight initial compression under low hardness
and then the methocarbamol granules are filled in the die cavity and the final compression
takes place with desired weight and hardness being set. 
Weight and the content uniformity of the two layers in the tablet are tested
6.6.2 Punch specifications:-
Upper punch – upper punches 19.1 X 8.9mm caplet shape, concave punches-embossing with
‘E/S’.
Lower punch- lower punches 19.1 X 8.9mm caplet shape, concave punches-embossing with
‘255’.
Dies - 19.1 X 8.9mm bore size. ‘B’ tooling
Temperature and relative humidity record
Temperature- 24-25ºC
RH- 50-51%
6.6.3 Compression Parameters:-
Description  of  tablet  -  white  and  green  coloured,  caplet  shape  bilayer  tablets  with  255
engraving on white side and ES engraving on green side with score line between ES.
Weight of white layer [acetaminophen] - 555.0mg±5% [527.3mg-582.8mg]
Weight of green layer [methocarbamol] - 482.0mg±5% [457.9mg-506.1mg]
Weight of 20 tablets – 20.74gm±2% [20.33gm-21.15gm]
Hardness – NLT 10kp
Thickness – 6.9mm±0.3mm
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Friability – NMT 0.8% w/w
Disintegration time – NMT 15min
Individual tablet weight variation – 1037mg±5% [985.0mg – 1089.0mg]
6.7 COATING PROCEDURE OF THE TABLETS:
                   Coating is done in the GLATT tablet hi coater with the optimized parameters for
uniform coating of the tablets without any rough service on the tablet and uniformity in the
coating  is  achieved  by stirring  the  coating  solution  continuously during  coating and  the
percentage of coating is properly checked by taking the average initial weight of 50 tablets
before coating and after coating 
6.7.1 Coating parameters:-
Inlet temperature – 70-80ºC
Exhaust temperature – 40-50ºC
Atomisation pressure – 3.0-4.0kg/cm2
Pan-rpm – 2.4rpm
Gun-bed distance – 20-30cm
Spray rate – 180-250ml/min/4guns
Peristal pump rpm – 15-16rpm
Preparation of coating solution:-
Take purified water having ambient temperature[15-35ºC] into a stainless steel vessel.
Check weight of advantia prime 199900BA01[18.85±0.1kg].
Stir purified water with stirrer to form vortex add advantia prime into vortex slowly.
Reduce the stirrer speed, so that no vortex should form and continue for 30-45min 
6.8 POST COMPRESSION PARAMETERS: 
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                       The quantitative evaluation and assessment of a tablet’s chemical, physical and
bioavailability properties are important in the design of tablets and to monitor product quality.
These  properties  are  important  since  chemical  breakdown  or  interactions  between  tablet
components may alter the physical tablet properties, and greatly affect the bioavailability of
the  tablet  system.  There  are  various  standards  that  have  been  set  in  the  various
pharmacopoeias regarding the quality of pharmaceutical tablets. These include the diameter,
size,  shape,  thickness,  weight,  hardness,  disintegration  and  dissolution  characters.  The
diameters and shape depends on the die and punches selected for the compression of tablets.
The  remaining  specifications  assure  that  tablets  do  not  vary  from one  production  lot  to
another. The following standards or quality control tests should be carried out on compressed
tablets.
1. General appearance
                 The general appearance of tablets, its visual identity and overall ‘elegance’ is
essential for consumer acceptance, control of lot-to-lot uniformity and general tablet-to-tablet
uniformity and for  monitoring the production process.  The control  of  general  appearance
involves measurement of attributes such as a tablet’s size, shape, color, presence or absence
of odor, taste, surface textures, physical flaws and consistency.
2. Size and shape
               The type of tooling determines the shape and dimensions of compressed tablets
during the compression process. At a constant compressive load, tablets thickness varies with
changes in die fill, particle size distribution and packing of the powder mix being compressed
and  with  tablet  weight,  while  with  a  constant  die  fill,  thickness  varies  with variation in
compressive load. Tablet thickness is consistent from batch to batch or within a batch only if
the tablet granulation or powder blend is adequately consistent in particle size and particle
size distribution, if the punch tooling is of consistent length, and if the tablet press is clean
and in good working condition.
3. Thickness
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The  thickness  of  individual  tablets  may  be  measured  with  a  micrometer,  which
permits accurate measurements and provides information of the variation between tablets.
Tablet  thickness  should  be  controlled  within  a  ± 5% variation  of  a  standard  value.  Any
variation in thickness within a particular lot of tablets or between manufacturer’s lots should
not  be apparent  to  the unaided eye  for  consumer acceptance of the product.  In  addition,
thickness must be controlled to facilitate packaging.
The physical dimensions of the tablet along with the density of the material in the
tablet formulation and their proportions,  determine the weight of the tablet.  The size and
shape of the tablet can also influence the choice of tablet machine to use, the best particle size
for granulation, production lot size that can be made, the best type of tableting processing that
can be used, packaging operations, and the cost of production.
4. Weight variation
                   This test is also known as uniformity of weight. This does not apply to layer or
enteric coated tablets. Weights of individual 20 tablets was noted and their mean weight was
calculated, and the percentage deviation was calculated by using the formula
                       Percentage deviation = X- X  1    x100 
                                                           X   
Where, 
            X = actual weight of the tablet
           X1 = average weight of the tablet 
5. Content uniformity
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                    The content uniformity test is used to ensure that every tablet contains the
amount of drug substance intended with little variation among tablets within a batch. Due to
increased  awareness  of  physiological  availability,  the  content  uniformity  test  has  been
included in the monographs of all coated and uncoated tablets and all capsules intended for
oral administration where the ranges of size of the dosage form available include 50mg or
smaller sizes. Tablet monographs with a content uniformity requirement do not have weight
variation requirements4. For content uniformity test, representative samples of 30tablets are
selected and 10 are assayed individually. At least 9 must assay within ±15% of the declared
potency and none may exceed ± 25%.
6. Friability
                  Friction and shock are the forces that most often cause tablets to chip, cap or
break. The friability test is closely related to tablet hardness and is designed to evaluate the
ability of the tablet to withstand abrasion in packaging, handling and shipping. It is usually
measured by the use of the Roche friabilator. A number of tablets are weighed and placed in
the apparatus where they are exposed to rolling and repeated shocks as they fall 6 inches in
each turn within the apparatus. After four minutes of this treatment or 100 revolutions, the
tablets are weighed and the weight compared with the initial weight. The loss due to abrasion
is a measure of the tablet  friability.  The value is  expressed as a percentage.  A maximum
weight loss of not more than 1% of the weight of the tablets being tested during the friability
test is considered generally acceptable and any broken or smashed tablets are not picked up.
Normally, when capping occurs, friability values are not calculated. A thick tablet may have
fewer tendencies to cap whereas thin tablets of large diameter often show extensive capping,
thus indicating that tablets with greater thickness have reduced internal stress.
                                Friability index = Initial weight – Final weight 
                                                                   Initial weight
7. Hardness
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                   The resistance of tablets to capping, abrasion or breakage under conditions of
storage,  transportation  and  handling  before  usage  depends  on  its  hardness.  It  is  now
designated as either the Monsanto or Stokes hardness tester. The instrument measures the
force  required  to  break  the  tablet  when  the  force  generated  by  a  coil  spring  is  applied
diametrally to the tablet.
              Hardness, which is now more appropriately called crushing strength determinations
are made during tablet production and are used to determine the need for pressure adjustment
on tablet machine. If the tablet is too hard, it may not disintegrate in the required period of
time to meet the dissolution specifications; if it is too soft, it may not be able to withstand the
handling during subsequent processing such as coating or packaging and shipping operations.
The force required to break the tablet is measured in kilograms and a crushing strength of
4Kg is usually considered to be the minimum for satisfactory tablets2. Oral tablets normally
have a hardness of 4 to 10kg; however, hypodermic and chewable tablets are usually much
softer (3 kg) and some sustained release tablets are much harder (10-20 kg). Tablet hardness
has  been  associated  with  other  tablet  properties  such  as  density  and  porosity.  Hardness
generally  increases  with  normal  storage  of  tablets  and  depends  on  the  shape,  chemical
properties, binding agent and pressure applied during compression.
8. Dissolution
                      Dissolution is the process by which a solid solute enters a solution. In the
pharmaceutical industry, it may be defined as the amount of drug substance that goes into
solution per unit time under standardized conditions of liquid/solid interface, temperature and
solvent composition.
                     Dissolution behavior of drugs has a significant effect on their pharmacological
activity. In fact, a direct relationship between in vitro dissolution rate of many drugs and their
Solid dosage forms may or may not disintegrate when they interact with gastrointestinal fluid
following oral administration depending on their design.
Figure No: 4 Schematic diagram of the dissolution process
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                    Dissolution kinetics is important in determining the bioavailability of a drug.
Levy and some other workers reported that the dissolution rate controls the rate of build up of
certain drugs in the blood stream. It  was thus recognized that in-vitro dissolution kinetics
provides  useful  information on the  availability of  drugs  and  their  subsequent  therapeutic
effects  in-vivo.  The  various  pharmacopoeias  contain  specifications  on  the  dissolution
requirements of various drugs. A variety of designs of apparatus for dissolution testing have
been proposed and tested, varying from simple beaker with stirrer to complex systems with
lipid phases and lipid barrier where an attempt is made to mimic the biological milieu. The
choice of the apparatus to be used depends largely on the physicochemical properties of the
dosage form.
Two types of methods are employed for performing the in vitro dissolution studies
1. Basket type
2. Paddle type
1. Basket type
Basket method is used for evaluating the formulations that tend to float while carrying out the
dissolution study. Floating can be due to swelling of the formulation by taking some amount
of dissolution media which makes the formulation lighter than the dissolution medium. So, in
this method the formulation is entrapped inside the basket that will not allow the formulation
to float even if it swells and becomes lighter than the dissolution medium.
2. Paddle type
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Paddle method can be used for floating formulations and those formulations that don’t float
even after swelling. The dissolution apparatus consists of a cylindrical vessel made of glass or
inert transparent material. The volume of the vessel generally used was 900 ml. In the vessel
dissolution media was taken and the formulation to be evaluated had to be placed in it. A
shaft is present which is connected at one end to a motor and the other end to a basket or
paddle according to the method employed.
For basket method unless otherwise specified 40-mesh size for the basket was used. The rpm
of  the  shaft  was  100 rpm for  basket  method and  50 rpm for  paddle method.  In  regular
intervals of time samples were withdrawn from the vessel and analyzed for the drug release
up to each interval by UV Visible spectrophotometer. After withdrawing the sample it was
replaced with same amount of dissolution medium to maintain sink conditions.
8.1 Dissolution for Acetaminophen
Medium : 900 ml of phosphate buffer pH 5.8
RPM             : 50
Time              :  5, 10, 15, 30, 45, 60.
Apparatus  :  Paddle.
Temperature  : 370 C ± 0.50 C
Preparation of buffer pH 5.8
Solution A: 0.2M Monobasic potassium phosphate(KH2PO4):
Weigh about 27.22gm of potassium di hydrogen phosphate in 1000 ml volumetric flask and
dissolve in 300ml of purified water and make up to volume with purified water.
Solution B: 0.2M Sodium hydroxide solution:
Weigh about  0.8gm of sodium hydroxide pellets  in  100ml volumetric  flask add 60ml of
purified water and dissolve. Make up to volume with purified water.
Dissolution Medium preparation (USP Phosphate buffer pH 5.8):
Take 250ml of solution A and add 18ml solution B , make up to the volume of 1000ml with
purified water. Adjust the pH 5.8+/- 0.05 with 0.2M sodium hydroxide solution if necessary.
Sample Preparation
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Place one tablet in each of the 6 bowls containing 900ml of media that has been equilibrated
to 37oc+/-0.5 Take care to exclude air  bubbles from surface of  tablet.  Withdraw 10ml of
sample after completion of 5min from each dissolution bowl. After withdrawal of sample
replace 10ml of Buffer pH 5.8 maintained at 370 ± 0.50 C.  Follow the same procedure after
completion of 10, 15, 30, 45min. Samples are  withdrawn  from  a  zone  midway  between
surface of dissolution medium and top of rotating paddle, not less than 1cm from the vessel
wall and filter through Millex – HV 0.45micron PVDF filter, and inject solution directly in to
HPLC.
Standard Preparation
Weigh accurately about 55.0 mg of Acetaminophen working Standard and transfer to a 100
ml volumetric flask shake with sufficient dissolution medium, sonicate to dissolve and make
up the volume with dissolution media. Filter through 0.45 micron HDPE filter.   
Procedure:
Separately inject equal volumes of Mobile phase, Blank (Dissolution media), standard (Five
replicate  injections)  and  sample  preparation,  record  the  chromatograms,  and  measure  the
areas for the Acetaminophen. Calculate the quantity of acetaminophen.
System suitability:
Chromatograph the standard preparation, and record the peak responses as directed
1) The relative standard deviation for five replicate injections of standard
of Acetaminophen is not more than 2%
2) Tailing factors for Acetaminophen peak are not more than 2
Calculation:
      
TA        .           SW              900              P           
            ------------ X   ---------- X   ------   X    ------   X 100 
SA                     100              L.A           100            
Where,
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SA = Peak area due to Acetaminophen in standard preparation
TA = Peak area due to Acetaminophen in sample preparation
SW = Weight of Acetaminophen working standard in mg
   P =  Purity of  Acetaminophen working standard
L.A = Labeled amount of acetaminophen  in mg
8.2 Dissolution for Methocarbamol:
Standard Preparation
Weigh accurately about 44.0 mg of Methocarbamol working Standard and transfer to a 100
ml volumetric flask shake with sufficient dissolution medium, sonicate to dissolve and make
up the volume with dissolution media. Filter through 0.45 micron HDPE filter.
Procedure:
Separately inject equal volumes of Mobile phase, Blank (Dissolution media), standard (Five
replicate  injections)  and  sample  preparation,  record the  chromatograms,  and  measure  the
areas for the Methocarbamol.
System suitability:
Chromatograph the standard preparation, and record the peak responses as directed
The relative standard deviation for five replicate injections of standard
of Methocarbamol is not more than 2%
1) Tailing factors for Methocarbamol peak are not more than 2
Calculation:
      
TA        .           SW              900              P           
            ------------ X   ---------- X   ------   X    ------   X 100 
SA                     100              L.A           100            
Where,
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SA = Peak area due to Methocarbamol  in standard preparation
TA = Peak area due to Methocarbamol in sample preparation
SW = Weight of Methocarbamol working standard in mg
   P =  Purity of  Methocarbamol working standard
L.A = Labeled amount of Methocarbamol  in mg
9. DRUG CONTENT
Chromatographic conditions:
Column – L1, 100*4.6mm,5µ
                  [Develosil ODS-MG-5,100*4.6,5µ is suitable]
Flow rate – 1.0mL/min
Wave length – 273nm
Injection volume - 140µL
Column oven temp - 25C ± 2C
Run time – 7min
Mobile phase:-  
Prepare a mixture of milli Q water, methanol, glacial acetic acid in the ratio of 600:400:15. 
Filter through 0.45µ PVDF filter and degas.
Diluent preparation:-
Prepare a mixture of milli Q water and methanol in the ratio of 600:400. Filter through 0.45µ 
PVDF filter and degas.
Standard preparation:-
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Accurate weigh and transfer of 50mg of acetaminophen and 40mg of Methocarbamol 
working standard in to a 200ml of volumetric flask, add sufficient amount of diluent, sonicate
to dissolve and make up volume with diluent. Prepare the standard in duplicate [i.e standard 
‘A’ and standard ‘B’] and calculate the recovery of the standard B using the formula.
 Area of standard A           Weight of standard B
————————   *     —————————   *   purity of standard.
Area of standard B            Weight of standard A
Sample preparation:-
Weigh and finely powder not fewer than 20tabs. Transfer about 1047 mg of the powder 
equivalent to about 500mg of acetaminophen and 400mg of Methocarbamol into a 200ml 
volumetric flask. To it add 100ml of diluent. Sonicate for 30min and make up to volume with 
diluent. Filter the solution through 0.45µ miller HV PVDF. Further dilute 5ml to 50ml with 
diluent.
Procedure:-
Separately inject 10µL mobile phase. The blank [diluent] standard ‘A’ preparation [five 
replicate injections]. Standard ‘B’ preparation [duplicate injection] into the chromatograph. 
Record the chromatograms, and measure responses for the major peaks.
Calculate % release of acetaminophen and Methocarbamol comparing with standard A. 
System suitable:-
Chromatograph the standard preparation and record the peak responses as directed.
1] The related standard deviation for five replicate injections of standard for both 
acetaminophen and Methocarbamol is not more than 2.0%.
2] The tailing factor for the acetaminophen and Methocarbamol peak are not more than 2.0.
Calculation:-
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% of Acetaminophen =
  TA                SW                  200                50                                    P              100
---------   X    ---------     X   ---------   X   ---------    X Avg.wt X   --------   X   -------
  SA                200                   TW                5                                    100             LA
Where,
TA = Peak area due to acetaminophen in sample preparation
SA = Peak area due to acetaminophen in standard preparation
SW = Weight of acetaminophen working standard in mg
   P = Purity of acetaminophen working standard
LA = Labelled amount of acetaminophen in mg
TW = weight of sample taken in mg
% of Methocarbamol = 
  TA               SW                200               50                                    P               100
---------   X    ---------     X   ---------   X   ---------    X Avg wt. X   --------   X    -------
 SA                200                TW                5                                    100             LA
Where,
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TA = Peak area due to methocarbamol in sample preparation
SA = Peak area due to methocarbamol in standard preparation
SW = Weight of methocarbamol working standard in mg
   P = Purity of methocarbamol working standard
LA = Labelled amount of methocarbamol in mg
TW = weight of sample taken in mg
B) Drug Excipient Compatibility Study
The compatibility of drug and formulation components was important  prerequisite  before
formulation.  It  is  therefore  necessary  to  confirm  that  the  drug  does  not  react  with  the
polymers and excipients under experimental conditions and affect the shelf life of product or
any other unwanted effects on the formulation. 
Procedure:
Drug was mixed with excipients in different ratio. These mixtures were kept in a 5ml
glass white colored vials and packed properly. These vials are exposed to room temperature
and 40˚c/75%RH. 2-3gm of blend was prepared which was filled in 3 vials. Observations for
physical appearance were made at zero weeks, 1 month, the samples were withdrawn for
analysis of appearance, moisture content, assay & related substance.
    
7. RESULTS AND DISCUSSION
R.V.S COLLEGE OF PHARMACEUTICAL SCIENCES, COIMBATORE. Page 74
7.1 PHYSIOCHEMICAL PARAMETERS:
1. DESCRIPTION: 
Table No: 37 Description
S.N
o 
RAW
MATERIAL
(API)
COLOUR ODOUR NATURE
1 Acetaminophen White Odour less Crystalline
powder
2 Methocarbamol White Odour less Crystalline
powder
2. SOLUBILITY:
Table No: 38 Solubility
S. No RAW MATERIAL (API) SOLUBILITY
1 Acetaminophen
Water - Slightly soluble
Organic solvents - Soluble
2 Methocarbamol
Water                 -       Sparingly soluble     
Chloroform          -     Sparingly soluble
Propylene glycol   -    Soluble
Benzene                -     Insoluble
n-hexane                 -    Insoluble
3. pH: 
Table No: 39 pH
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S.No RAW MATERIAL 
(API)
SOLUTION 
CONCENTRATION
pH
1 Acetaminophen 1mg/ml 5.9
2 Methocarbamol 1mg/ml 5.4
4. MELTING POINT:
Table No: 40 Melting point
S. No RAW MATERIAL (API) OBSERVED VALUE
1 Acetaminophen 170.8⁰C
2 Methocarbamol 95.2⁰C
5. CHEMICAL NATURE: 
Table No: 41 Acetaminophen & Methocarbamol specifications.
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S.NO PARAMETERS ACETAMINOPHEN METHOCARBAMOL
1 Molecular formula
C8H9NO2 C11H15NO5
2 Molecular weight 
151.16 241.24
3 IUPAC name 
N-(4 
hydroxyphenyl)acetamide
3-(2-methoxyphenoxy)-
1,2-propanediol 1-
carbamate
4 Chemical nature 
Synthetic, non opiate, 
centrally acting analgesic
Centrally acting anti 
inflamatory
6. HYGROSCOPICITY:
Table No: 42 Interpretation of results based on percent increase in mass.
S. No RAW MATERIAL (API) RESULT
1 Acetaminophen Not hygroscopic
2 Methocarbamol Not hygroscopic
7. LOSS ON DRYING:
Table No: 43 Loss on drying.
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S. No RAW MATERIAL (API) OBSERVED LOD
1 Acetaminophen 0.22%
2 Methocarbamol 0.28%
8. SIEVE ANALYSIS:
Table No: 44 Sieve analysis.
S. No RAW MATERIAL (API) NATURE OF SAMPLE
1 Acetaminophen Fine powder
2 Methocarbamol Fine powder
9. FLOW PROPERTY MEASUREMENT: 
• ANGLE OF REPOSE:
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Table No: 45 Flow property and corresponding angle of repose.
S. No RAW MATERIAL (API) ANGLE OF REPOSE 
(DEGREES)
FLOW 
PROPERTY 
1 Acetaminophen 41.2o Very poor
2 Methocarbamol 40.81o Very poor
• DENSITY: 
 BULK DENSITY:
Table No: 46 Bulk Density.
S. No RAW MATERIAL (API) BULK DENSITY  (PI) (g/ml)
1 Acetaminophen 0.6
2 Methocarbamol 0.4
 TAPPED DENSITY:
Table No: 47 Tapped Density.
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S. No RAW MATERIAL (API) TAPPED DENSITY (Pt) (g/ml)
1 Acetaminophen 0.573
2 Methocarbamol 0.39
 COMPRESSIBILTY INDEX:
Table No: 48 Compressibilty Index.
S. No RAW MATERIAL 
(API) 
COMPRESSIBILTY INDEX
(%) 
FLOW 
PROPERTY 
1 Acetaminophen 27.32 Poor
2 Methocarbamol 28.61 Poor
 HAUSNER RATIO:
Table No:49 Hausner’s ratio.
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S. No RAW MATERIAL 
(API) 
HAUSNER 
RATIO
FLOW 
PROPERTY 
1 Acetaminophen 1.37 Poor
2 Methocarbamol 1.41 Poor
10. DRUG CONTENT: 
Table No: 50 Drug Content
S. No RAW MATERIAL (API) ASSAY ( % )
1 Acetaminophen 99.78
2 Methocarbamol 99.62
7.2 COMPATIBILITY STUDIES:
Table No: 51 Compatibility Studies of Acetaminophen With Excipients.
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Drug Excipients
( Ratio= 1:1)
1st day 1st week  2nd week  3rd week 
400C & 75%
RH
400C & 75%
RH
400C & 
75% RH
400C & 75% 
RH
A Methocarbamol Nd Nd Nd Nd
A Pregelatinized
starch
Nd Nd Nd Nd
A PVP K-30 Nd Nd Nd Nd
A Sodium  Starch
Glycolate
Nd Nd Nd Nd
A Stearic Acid Nd Nd Nd Nd
Where,
                   A= Acetaminophen
                   RH= Relative humidity        
                   Nd = change not detectable
Figure No: 5 IR Spectra of Acetaminophen
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Figure No: 6 IR Spectra of Acetaminophen and Methocarbamol
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Figure No: 7 IR Spectra of Acetaminophen ,PVP K-30 and Microcrystalline cellulose
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Inference: The IR spectra of pure drug Acetaminophen and physical mixture with other 
excipients were compared and are found to be compatable with each other as indicated by no 
significant change in the drug peaks.
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Table No: 52 Compatibility Studies of Methocarbamol With Excipients.
Drug Excipients
( Ratio= 1:1)
1st day 1st week  2nd week  3rd week 
400C & 
75% RH
400C & 
75% RH
400C & 
75% RH
400C & 
75% RH
M Acetaminophen Nd Nd Nd Nd
M Pregelatinized
starch
Nd Nd Nd Nd
M Micro  crystalline
cellulose
Nd Nd Nd Nd
M PVP K-30 Nd Nd Nd Nd
M Sodium  Lauryl
sulphate
Nd Nd Nd Nd
M Sodium  Starch
Glycolate
Nd Nd Nd Nd
M Colloidal  Silicon
di oxide
Nd Nd Nd Nd
Where,
                   M= Methocarbamol
                   RH= Relative humidity        
                   Nd = change not detectable
Figure No: 8 IR Spectra of Methocarbamol
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Figure No: 9 IR Spectra of Methocarbamol, PVP K-30 and Microcrystalline cellulose
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Inference:  The IR spectra  of pure  drug Methocarbamol  and physical  mixture with other
excipients were compared and are found to be compatable with each other as indicated by no
significant change in the drug peaks between pure drug sample and drug excipient physical
mixture.
7.3 PRE COMPRESSION PARAMETER:
Table No: 53 Precompression Parameter of Acetaminophen Granules Trials:
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Formulations Bulk
density
(gm/cm2)
Tapped
density
(gm/cm2)
C.I (%) Angle of
repose
(0)
H.R Moisture
Content
F1 0.44 0.55 27.0 50⁰.12’ 1.44 0.681
F2 0.41 0.51 28.33 47⁰.32’ 1.42 0.630
F3 0.43 0.52 27.3 48⁰.26’ 1.382 0.612
F4 0.41 0.51 29.61 46⁰.56’ 1.255 0.586
F5 0.42 0.54 32.22 42⁰.21’ 1.383 0.323
F6 0.49 0.50 20.0 38⁰.65’ 1.222 0.311
F7 0.48 0.55 18.15 36⁰.23’ 1.25 0.262
F8 0.48 0.51 15.69 28⁰.13’ 1.146 0.216
F9 0.47 0.55 20.0 30⁰.23’ 1.25 0.218
Inference: Formulations F1 to F5 has high angle of repose and Hausners ratio indicating 
poor flow of granules and the flow property increased in case of F6 and F7 because of 
inclusion of a dry binder and F8 and F9 has shown good flow as indicated by angle of repose 
and Hausners ratio because of increase in concentration of lubricant Stearic acid
Table No: 54 Precompression Parameter of Methocarbamol Granules Trials:
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Formulations Bulk
density
(gm/cm2)
Tapped
density
(gm/cm2)
C.I (%) Angle of
repose
(0)
H.R Moisture
Content
F1 0.45 0.56 28.64 46⁰.66’ 1.39 0.621
F2 0.44 0.57 31.8 48⁰.2’ 1.38 0.627
F3 0.41 0.59 30.5 50⁰.56’ 1.40 0.612
F4 0.44 0.57 32.8 46⁰.99’ 1.383 0.531
F5 0.44 0.56 24.42 47⁰.3’ 1.382 0.523
F6 0.43 0.54 20.37 42⁰.21’ 1.255 0.322
F7 0.47 0.59 18.64 34⁰.56’ 1.208 0.292
F8 0.48 0.58 17.24 30⁰.12’ 1.124 0.242
F9 0.45 0.55 18.18 31⁰.63’ 1.125 0.245
Inference: Formulation F1 to F7 has high angle of repose and Hausners ratio and the values 
reduced by addition of increasing concentration of Sodium lauryl sulphate as lubricant that 
enhanced flow property.
7.4 POST COMPRESSION PARAMETER OF ACETAMINOPHEN AND 
METHOCARBAMOL TABLETS:
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 Table No: 55 Post Compression Parameter of Acetaminophen and Methocarbamol Tablets.
Formulation
s
Weight
Variation
(mg)
Hardness
(kg/cm2)
Thickness
(mm)
Disintegration
time (min)
Friability
(%)
F1 1025-1033 17.1 6.72 16 0.008
F2 1020-1030 16.8 6.66 12 0.068
F3 1015-1032 8.9 6.74 6 1.062
F4 1032-1038 9.1 6.84 8 1.076
F5 1004-1034 11.1 6.63 7 0.089
F6 1036-1045 14.3 6.88 4 1.174
F7 1012-1024 13 6.71 5 0.041
F8 980-1040 13.7 6.75 6 0.055
F9 1032-1039 13.3 6.72 5 0.050
7.5 DRUG CONTENT: 
Table No: 56 Drug Content Values of Acetaminophen and Methocarbamol
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7.6.1 INNOVATOR DRUG RELEASE PROFILE:
Table No: 57 Innovator Drug Release Profile:
TIME
(MIN)
INNOVATOR
(ACETAMINOPHEN)
INNOVATOR
(METHOCARBAMOL)
10 72.4% 70.7%
15 84.2% 82.6%
30 93.2% 91.3%
45 96.8% 94.9%
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FORMULATIONS ACETAMINOPHEN METHOCARBAMOL
F5 98.12% 97.23%
F6 99.01% 98.25%
F7 100.02% 100.05%
F8 100.08% 100.03%
F9 100.05% 100.01%
60 98.2% 96.4%
7.6.2 DRUG RELEASE VALUES OF ACETAMINOPHEN AND METHOCARBAMOL
Table No: 58 Drug Release Values of Acetaminophen and Methocarbamol
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FORMULATIONS ACETAMINOPHEN METHOCARBAMOL
F5 95.8% 95.6%
F6 96.7% 90.2%
F7 96.6% 96.6%
F8 97.8% 97.2%
F9 96.1% 97.1%
7.6.3(A) RELEASE PROFILE OF ACETAMINOPHEN IN F6 COMPARED WITH 
INNOVATOR
Table No: 59 Comparitive release of Acetaminophen from innovator and F6
Time(min) % Release of innovator % Release from F6
10 72.4 85.8
15 84.2 90.1
30 93.2 92.5
45 96.8 95.2
60 98.2 96.7
Figure No: 10 Comparitive release of Acetaminophen from innovator and F6
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Inference: The  Release  profile  of  Acetaminophen  from  F6  was  compared  to  innovator
initially more release and then the release was less than inovator at the end of 45 and 60min
7.6.3(B) COMPARITIVE RELEASE OF METHOCARBAMOL FROM INNOVATOR 
AND F6
Table No: 60 Comparitive release of Methocarbamol from innovator and F6
Time(min) % Release of innovator % Release from F8
10 70.7 59.3
15 82.6 70.6
30 91.3 83.2
45 94.9 86.4
60 96.4 90.2
Figure No: 11 Comparitive release of Methocarbamol from innovator and F6
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Inference: The Release profile of Methocarbamol from F6 was compared to innovator and
the release rate was less than inovator at the end of 45 and 60min.
7.6.4(A) RELEASE PROFILE OF ACETAMINOPHEN IN F7 COMPARED WITH 
INNOVATOR
Table No: 61 Comparitive release of Acetaminophen from innovator and F7
Time(min) % Release of innovator % Release from F7
10 72.4 90.2
15 84.2 93.4
30 93.2 95.5
45 96.8 97.3
60 98.2 96.6
Figure No: 12 Comparitive release of Acetaminophen from innovator and F7
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Inference: The Release profile of Acetaminophen from F7 was more compared to innovator
initially and the release was less than inovator at the end of 45 and 60min.
7.6.4(B) COMPARITIVE RELEASE OF METHOCARBAMOL FROM INNOVATOR 
AND F7
Table No: 62 Comparitive release of Methocarbamol from innovator and F7
Time(min) % Release of innovator % Release from F7
10 70.7 60.5
15 82.6 73.6
30 91.3 85.6
45 94.9 89.7
60 96.4 91.5
Figure No: 13 Comparitive release of Methocarbamol from innovator and F7
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Inference: The Release profile of Methocarbamol from F7 was compared to innovator and
the release rate was less than inovator at the end of 45 and 60min.
7.6.5(A) COMPARITIVE RELEASE OF ACETAMINOPHEN FROM INNOVATOR 
AND F8
Table No: 63 Comparitive release of Acetaminophen from innovator and F8
Time(min) % Release of innovator % Release from F8
10 72.4 70.4
15 84.2 83.1
30 93.2 91.7
45 96.8 95.2
60 98.2 97.8
Figure No: 14 Comparitive release of Acetaminophen from innovator and F8
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Inference: The Release profile of Acetaminophen from F8 was compared to innovator and
the release was almost equal and comparable to that of inovator at the end of 45 and 60min.
7.6.5(B) COMPARITIVE RELEASE OF METHOCARBAMOL FROM INNOVATOR 
AND F8
Table No: 64 Comparitive release of Methocarbamol from innovator and F8
Time(min) % Release of innovator % Release from F8
10 70.7 68.7
15 82.6 80.5
30 91.3 89.4
45 94.9 93.2
60 96.4 95.1
Figure No: 15 Comparitive release of Methocarbamol from innovator and F8
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Inference: The Release profile of Methocarbamol from F8 was compared to innovator and
the release was almost equal and comparable to that of inovator at the end of 45 and 60min.
7.6.6(A) RELEASE PROFILE OF ACETAMINOPHEN IN F9 COMPARED WITH 
INNOVATOR
Table No: 65 Comparitive release of Acetaminophen from innovator and F9
Time(min) % Release of innovator % Release from F9
10 72.4 70.1
15 84.2 81.9
30 93.2 91.2
45 96.8 94.8
60 98.2 97.0
Figure No: 16 Release profile of Acetaminophen in F9 compared with innovator
R.V.S COLLEGE OF PHARMACEUTICAL SCIENCES, COIMBATORE. Page 100
         
0.8 1 1.2 1.4 1.6 1.8 2 2.2
0
20
40
60
80
100
120
         % Drug release
 
Inference: The Release profile of Acetaminophen from F9 was compared to innovator and 
the release was less than that of inovator.
7.6.6(B) COMPARITIVE RELEASE OF METHOCARBAMOL FROM INNOVATOR 
AND F9
Table No: 66 Comparitive release of Methocarbamol from innovator and F9
Time(min) % Release of innovator % Release from F9
10 70.7 68.2
15 82.6 80.1
30 91.3 89.1
45 94.9 93.0
60 96.4 94.5
Figure No: 17 Comparitive release of Methocarbamol from innovator and F9
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Inference: The Release profile of Methocarbamol from F9 was compared to innovator and 
the release was less than that of inovator.
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Inference: HPLC Chromatogram showing peaks of Acetaminophen and Methocarbamol 
release from formulation F8.
7.6.7 COMPARISON OF DISSOLUTION PROFILE OF FORMULATIONS WITH 
INNOVATOR
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Table No: 67 Comparison of dissolution profile of formulations with innovator
Time
(min)
Innovator
     (A)
Innovator
     (M)
% Drug Release
A M A M A M A M
 F6  F6  F7  F7  F8  F8  F9  F9
10 72.4 70.7 85.8 59.3 90.2 60.5 70.4 68.7 70.1 68.2
15 84.2 82.6 90.1 70.6 93.4 73.6 83.1 80.5 81.9 80.1
30 93.2 91.3 92.5 83.2 95.5 85.6 91.7 89.4 91.2 89.1
45 96.8 94.9 95.2 86.4 97.3 89.7 95.2 93.2 94.8 93.0
60 98.2 96.4 96.7 90.2 96.6 91.5 97.2 95.8 97.0 95.4
Where,
A = Acetaminophen
M = Methocarbamol
7.6.8 COMPARATIVE RELEASE PROFILE OF ACETAMINOPHEN IN VARIOUS 
FORMULATION WITH INNOVATOR
Figure No: 18 Comparative release profile of Acetaminophen in various formulation with 
innovator
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Inference: Comparative release profile of Acetaminophen from various formulations 
showing that the release from formulation F8 matching with that of inovator
Figure No: 19 Methocarbamol release from various formulations compared to innovator 
Inference: Comparative release profile of Methocarbamol from various formulations 
showing that the release from formulation F8 matching with that of innovator.
7.7 STABILITY STUDY
7.7.1 STABILITY DATAS FOR OPTIMIZED FORMULATIONS AT 25⁰C & 60% RH 
FOR ACETAMINOPHEN AND METHOCARBAMOL BILAYER TABLETS
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Table No: 68 Stability Datas for Optimized Formulations at 25⁰C & 60 % RH for 
Acetaminophen and Methocarbamol Bilayer tablets
S.NO PARAMETERS STORAGE CONDITION (25⁰C & 60% RH)
INITIAL 30DAYS 45DAYS
1 Description White and Green
Coloured, Caplet Shaped
N.D N.D
2 Weight Variation 980-1040 Within limits Within
limits
3 Hardness (kg/cm2) 13.7 13.5 13.3
4 Thickness (mm) 6.75 6.75 6.75
5 Friability (%) 0.055 0.058 0.060
6 Disintegration Time 
(mins)
6 7 7
7 Drug Content (%)
(Acetaminophen)
100.08 100.05 100.02
8 Drug Content (%)
(Methocarbamol)
100.03 100.01 99.96
9 Drug Release (%)
(acetaminophen)
97.2% 97.01% 97.0%
10 Drug Release (%)
(Methocarbamol)
97.2% 96.8% 96.8%
11 Moisture Content 0.216 0.219 0.321
Table No: 69 Drug release of acetaminophen and methocarbamol at 25oC & 60%RH
Drug                                         % Drug release
Initial 30 Days 45 Days
Acetaminophen 97.2 97.01 97.0
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Methocarbamol 97.2 96.8 96.8
Figure No: 20 Drug release of acetaminophen and methocarbamol at 25oC & 60%RH
97.2
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96.8 96.8
Stability studies
Acetaminophen Methocarbamol
Inference: The drug release was not significantly reduced at the end of 30days and 45days 
storage at 25oC & 60%RH indicating stability of the formulation. All the parameters are with 
in the limits specified at the end of storage period.
7.7.2 STABILITY DATAS FOR OPTIMIZED FORMULATIONS AT 40⁰C & 75% RH 
FOR ACETAMINOPHEN AND METHOCARBAMOL BILAYER TABLETS
Table No: 70 Stability Datas for Optimized Formulations at 40⁰c & 75 % RH for 
Acetaminophen and Methocarbamol Bilayer tablets
S.NO PARAMETERS STORAGE CONDITION (40⁰C & 75% RH)
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INITIAL 30DAYS 45DAYS
1 Description White and Green
Coloured, Caplet Shaped
N.D N.D
2 Weight Variation 980-1040 980-1040 980-1040
3 Hardness (kg/cm2) 13.7 Within limits Within
limits
4 Thickness (mm) 6.75 6.75 6.75
5 Friability (%) 0.055 0.062 0.064
6 Disintegration Time 
(mins)
6 7 7
7 Drug Content (%)
(Acetaminophen)
100.08 100.03 100.0
8 Drug Content (%)
(Methocarbamol)
100.03 99.96 99.94
9 Drug Release (%)
(acetaminophen)
97.2% 97.0% 97.0%
10 Drug Release (%)
(Methocarbamol)
97.2% 96.6% 96.6%
11 Moisture Content 0.216 0.227 0.231
Table No: 71 Drug release of Acetaminophen and Methocarbamol at 40oC & 75%RH
Drug                                         % Drug release
Initial 30 Days 45 Days
Acetaminophen 97.2 97.0 97.0
Methocarbamol 97.2 96.6 96.6
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Figure No: 21 Drug release of Acetaminophen and Methocarbamol at 40oC & 75%RH
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Inference: The drug release was not significantly reduced at the end of 30days and 45days 
storage at 40oC & 75%RH indicating stability of the formulation. All the parameters are with 
in the limits specified at the end of storage period.
8. SUMMARY AND CONCLUSION
              The present study was aimed at developing a bilayer tablet of Acetaminophen and 
Methocarbamol.
            Totally 9 formulations are prepared with Acetaminophen and Methocarbamol granules
prepared separately in a rapid mixer granules.
            Pre compression parameters like Bulk density, True density, Angle of repose indicate 
all the formulations are showing good flow properties.
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            Tablets are compressed using SEJONG bilayer compression machine and tablets are 
evaluated for post compression parameters Weight variation, Hardness, Friability, 
Disintegration and Dissolution parameters.
             Formulations F1-F4 does not meet the direct criteria for Hardness and Disintegration 
time due to improper mixing of binder with the dry mixture.
             Formulations F5-F9 has shown post compression parameters within the specified 
limits of the innovator. The release profile of formulations F5-F9 was compared with 
innovator and all the formulations has shown a release of 70-95% and formulation F8 has 
matched the innovator release profile.
            The compressed belayer tablets was packed in blisters and subjected to stability 
studies at 40⁰C and 75% RH, 25⁰C and 60% RH. Samples were analyzed at regular intervals 
as mentioned in stability protocol.
From the study, it may be concluded that bilayer tablet of Acetaminophen and 
Methocarbamol can be prepared as immediate release formulation compared to conventional 
formulations.
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